Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.55 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 1/20 | 0.51 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.48 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | IDO1 | P14902 | 4/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.55 |
| ▸ | F2 | P00734 | 1/20 | 0.50 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | CA6 | P23280 | 1/20 | 0.48 |
| ▸ | CA5A | P35218 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27576463 | 1.00 | LOXL2 (0.67) | LOXL2TSHRIDO1ALDH1A1KCNJ1 | |
| Hydrochloric Acid SCHEMBL1820969 | 0.98 | LOXL2 (0.64) | LOXL2TSHRIDO1ALDH1A1KCNJ1 | |
| SCHEMBL335044 | 0.98 | LOXL2 (0.69) | LOXL2TSHRIDO1ALDH1A1KCNJ1 | |
| SCHEMBL19874575 | 0.96 | LOXL2 (0.67) | LOXL2TSHRIDO1ALDH1A1KCNJ1 | |
| Ammonia Solution, Strong SCHEMBL21518028 | 0.96 | LOXL2 (0.67) | LOXL2TSHRIDO1ALDH1A1KCNJ1 | |
| Bromide SCHEMBL11379599 | 0.96 | LOXL2 (0.67) | LOXL2TSHRIDO1ALDH1A1KCNJ1 | |
| Hydrochloric Acid SCHEMBL7504059 | 0.88 | LOXL2 (0.62) | LOXL2TSHRIDO1ALDH1A1KCNJ1 | |
| SCHEMBL20303796 | 0.87 | HPGD (0.58) | LOXL2TSHRIDO1ALDH1A1KCNJ1 | |
| Hydrochloric Acid SCHEMBL17260639 | 0.86 | LOXL2 (0.60) | LOXL2TSHRIDO1ALDH1A1KCNJ1 | |
| SCHEMBL43299 | 0.86 | LOXL2 (0.64) | LOXL2TSHRIDO1ALDH1A1KCNJ1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 520 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051295-A1 | PROCESS FOR THE PREPARATION OF MIRABEGRON FREE FROM GENOTOXIC IMPURITIES | ZYDUS LIFESCIENCES LIMITED (IN) | 2025-02-13 | — | — | US | claimed |
| CN-114560779-B | Synthesis method of mirabegron key intermediate | 杭州华东医药集团浙江华义制药有限公司 | 2024-06-25 | — | — | CN | claimed |
| CN-117230129-A | Method for preparing chiral arylamine compound by using aminotransferase or mutant thereof | 上海合全药业股份有限公司 | 2023-12-15 | — | — | CN | claimed |
| CN-116555211-A | Method for preparing chiral lactam compound by using aminotransferase mutant | 上海合全药业股份有限公司 | 2023-08-08 | — | — | CN | claimed |
| CN-116555366-A | Method for preparing chiral lactam compound by using aminotransferase mutant | 上海合全药物研发有限公司 | 2023-08-08 | — | — | CN | claimed |
| CN-116555364-A | Preparation method of aminocyclohexyl compound | 上海合全药业股份有限公司 | 2023-08-08 | — | — | CN | claimed |
| CN-116411033-A | Aminotransferase mutant from bacillus megatherium and application thereof | 上海合全药业股份有限公司 | 2023-07-11 | — | — | CN | claimed |
| CN-114645027-A | Aminotransferase mutant from bacillus megatherium and application thereof | 上海合全药物研发有限公司 | 2022-06-21 | — | — | CN | claimed |
| CN-114560779-A | Synthesis method of mirabegron key intermediate | 杭州华东医药集团浙江华义制药有限公司 | 2022-05-31 | — | — | CN | claimed |
| US-20200131431-A1 | CHEMICAL ADDITIVES AND SURFACTANT COMBINATIONS FOR FAVORABLE WETTABILITY ALTERATION AND IMPROVED HYDROCARBON RECOVERY FACTORS | ALCHEMY SCIENCES INC (US) | 2020-04-30 | — | — | US | claimed |
| US-9737875-B2 | Affinity reagents for protein purification | IMPOSSIBLE FOODS INC. (US) | 2017-08-22 | — | — | US | claimed |
| CN-102971288-B | Novel process for producing bisaminophenylalkylurea | NISSAN CHEMICAL IND LTD | 2015-01-21 | — | — | CN | claimed |
| WO-2014132270-A2 | PROCESS FOR THE PREPARATION OF 2-(2-AMINOTHIAZOL-4-YL)-N-[4-(2-{[(2R)-2-HYDROXY-2-PHENYL ETHYL]AMINO}ETHYL)PHENYL]ACETAMIDE MONOHYDROCHLORIDE, ITS INTERMEDIATES AND POLYMORPH THEREOF | MSN LABORATORIES LIMITED (IN) | 2014-09-04 | — | — | WO | claimed |
| CN-102971288-A | Novel process for producing bisaminophenylalkylurea | NISSAN CHEMICAL IND LTD | 2013-03-13 | — | — | CN | claimed |
| US-7109377-B2 | Synthesis of combinatorial libraries of compounds reminiscent of natural products | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2006-09-19 | — | — | US | claimed |
| US-20030082830-A1 | Synthesis of combinatorial libraries of compounds reminiscent of natural products | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-05-01 | — | — | US | claimed |
| US-6448443-B1 | GENERATED FROM DIVERSIFIABLE SCAFFOLDS SYNTHESIZED FROM THE PYRIDINE-BASED TEMPLATE ISONICOTINAMIDE; ALSO PROVIDES A NOVEL ORTHO-NITROBENZYL PHOTOLINKER; SYNTHESIZED FROM A SHIKIMIC ACID BASED EPOXYOL TEMPLATE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2002-09-10 | — | — | US | claimed |
| WO-2000006525-A9 | SYNTHESIS OF COMBINATORIAL LIBRARIES OF COMPOUNDS REMINISCENT OF NATURAL PRODUCTS | HARVARD COLLEGE (US) | 2000-04-20 | — | — | WO | claimed |
| WO-2000006525-A2 | SYNTHESIS OF COMBINATORIAL LIBRARIES OF COMPOUNDS REMINISCENT OF NATURAL PRODUCTS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2000-02-10 | — | — | WO | claimed |
| JP-10204046-A | — | — | None | — | — | JP | disclosed |
| US-20260131016-A1 | NOVEL AURISTATIN ANALOGS AND IMMUNOCONJUGATES THEREOF | ADCENTRX THERAPEUTICS INC (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4617261-A1 | 2,4,5-TRISUBSTITUTED PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | Wenzhou Medical University (CN) | 2025-09-17 | — | — | EP | disclosed |
| US-12404249-B2 | Heterocyclic derivatives and use thereof | C&C RESEARCH LABORATORIES (KR) | 2025-09-02 | — | — | US | disclosed |
| EP-3802495-B1 | 4-(2-((2-CHLOROQUINOLIN-4-YL)AMINO)ETHYL)BENZENESULFONAMIDE DERIVATIVES AS STAT3 INHIBITORS FOR THE TREATMENT OF CANCER | C&C RES LAB (KR) | 2025-07-02 | — | — | EP | disclosed |
| US-20250082762-A1 | NOVEL BIFUNCTIONAL HETEROCYCLIC COMPOUND HAVING BTK DEGRADATION FUNCTION VIA UBIQUITIN PROTEASOME PATHWAY, AND USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2025-03-13 | — | — | US | disclosed |
| US-20250073341-A1 | BIFUNCTIONAL HETEROCYCLIC COMPOUND HAVING BTK DEGRADATION FUNCTION VIA UBIQUITIN PROTEASOME PATHWAY, AND USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2025-03-06 | — | — | US | disclosed |
| US-20250074904-A1 | NSD2-TARGETED CHECMICAL DEGRADERTS AND COMPOSITIONS AND METHODS OF USE THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2025-03-06 | — | — | US | disclosed |
| US-20250051295-A1 | PROCESS FOR THE PREPARATION OF MIRABEGRON FREE FROM GENOTOXIC IMPURITIES | ZYDUS LIFESCIENCES LIMITED (IN) | 2025-02-13 | — | — | US | disclosed |
| CN-119219513-A | Preparation method of milbegron and intermediate thereof | 浙江华海药业股份有限公司 | 2024-12-31 | — | — | CN | disclosed |
| US-12161722-B2 | Bifunctional heterocyclic compound having BTK degradation function via ubiquitin proteasome pathway, and use thereof | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2024-12-10 | — | — | US | disclosed |
| CN-115894381-B | 2,4, 5-Trisubstituted pyrimidine compound and preparation method and application thereof | 温州医科大学 | 2024-10-18 | — | — | CN | disclosed |
| EP-4426714-A1 | NOVEL AURISTATIN ANALOGS AND IMMUNOCONJUGATES THEREOF | Adcentrx Therapeutics Inc. (US) | 2024-09-11 | — | — | EP | disclosed |
| US-20240285778-A1 | NOVEL BIFUNCTIONAL HETEROCYCLIC COMPOUND HAVING BTK DEGRADATION FUNCTION VIA UBIQUITIN PROTEASOME PATHWAY, AND USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2024-08-29 | — | — | US | disclosed |
| CN-118541378-A | Novel auristatin analogues and immunoconjugates thereof | 艾德森特克斯治疗股份有限公司 | 2024-08-23 | — | — | CN | disclosed |
| CN-114560779-B | Synthesis method of mirabegron key intermediate | 杭州华东医药集团浙江华义制药有限公司 | 2024-06-25 | — | — | CN | disclosed |
| WO-2024099168-A1 | 2,4,5-TRISUBSTITUTED PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | 温州医科大学 | 2024-05-16 | — | — | WO | disclosed |
| EP-4361153-A1 | NOVEL BIFUNCTIONAL HETEROCYCLIC COMPOUND HAVING BTK DEGRADATION FUNCTION VIA UBIQUITIN PROTEASOME PATHWAY, AND USE THEREOF | Korea Research Institute of Chemical Technology (KR) | 2024-05-01 | — | — | EP | disclosed |
| CN-117886701-A | Full-continuous preparation method of 4-nitrophenethylamine | 爱斯特（成都）生物制药股份有限公司 | 2024-04-16 | — | — | CN | disclosed |
| CN-117836299-A | Novel bifunctional heterocyclic compounds with Bruton tyrosine kinase decomposition via ubiquitin proteasome pathway and uses thereof | 韩国化学研究院 | 2024-04-05 | — | — | CN | disclosed |
| CN-112204010-B | Heterocyclic derivatives and uses thereof | C&C新药研究所 | 2024-03-19 | — | — | CN | disclosed |
| CN-117460743-A | Small molecule VE-PTP inhibitors | 曼宁研究公司 | 2024-01-26 | — | — | CN | disclosed |
| CN-117230129-A | Method for preparing chiral arylamine compound by using aminotransferase or mutant thereof | 上海合全药业股份有限公司 | 2023-12-15 | — | — | CN | disclosed |
| CN-116964044-A | Acetamido-phenyltetrazole derivatives and methods of use thereof | 希华医药有限公司 | 2023-10-27 | — | — | CN | disclosed |
| EP-3677674-B1 | TRANSAMINASE MUTANT AND USE THEREOF | ASYMCHEM LIFE SCIENCE TIANJIN CO LTD (CN) | 2023-10-04 | — | — | EP | disclosed |
| US-11739089-B2 | Acetamido-phenyltetrazole derivatives and methods of using the same | ATHENEX, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| EP-4225747-A1 | ACETAMIDO-PHENYLTETRAZOLE DERIVATIVES AND METHODS OF USING THE SAME | Athenex, Inc. (US) | 2023-08-16 | — | — | EP | disclosed |
| CN-116555211-A | Method for preparing chiral lactam compound by using aminotransferase mutant | 上海合全药业股份有限公司 | 2023-08-08 | — | — | CN | disclosed |
| CN-116555366-A | Method for preparing chiral lactam compound by using aminotransferase mutant | 上海合全药物研发有限公司 | 2023-08-08 | — | — | CN | disclosed |
| CN-116555364-A | Preparation method of aminocyclohexyl compound | 上海合全药业股份有限公司 | 2023-08-08 | — | — | CN | disclosed |
| CN-116411033-A | Aminotransferase mutant from bacillus megatherium and application thereof | 上海合全药业股份有限公司 | 2023-07-11 | — | — | CN | disclosed |
| WO-2023091565-A1 | NSD2-TARGETED CHEMICAL DEGRADERS AND COMPOSITIONS AND METHODS OF USE THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2023-05-25 | — | — | WO | disclosed |
| WO-2023081230-A1 | NOVEL AURISTATIN ANALOGS AND IMMUNOCONJUGATES THEREOF | ADCENTRX THERAPEUTICS INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| EP-4164690-A1 | SMALL MOLECULE VE-PTP INHIBITORS | Ripka, Amy (US) | 2023-04-19 | — | — | EP | disclosed |
| CN-115894381-A | 2,4,5-trisubstituted pyrimidine compound and preparation method and application thereof | 温州医科大学 | 2023-04-04 | — | — | CN | disclosed |
| CN-107619432-B | Glycopeptide derivative and pharmaceutically acceptable salt, preparation method and application thereof | 上海来益生物药物研究开发中心有限责任公司 | 2023-03-17 | — | — | CN | disclosed |
| WO-2023024545-A1 | FGFR4 INHIBITOR AND COMPOSITION, AND USES THEREOF IN DRUG PREPARATION | 中南大学湘雅医院 | 2023-03-02 | — | — | WO | disclosed |
| CN-112079724-B | Preparation method of dehydroxy mirabegron and intermediate thereof | 南京易亨制药有限公司（CN） | 2023-01-13 | — | — | CN | disclosed |
| CN-111263761-B | Novel polymer and diamine compound | 日产化学株式会社 | 2022-11-04 | — | — | CN | disclosed |
| US-20220332695-A1 | UREA DERIVATIVES AS CB1 ALLOSTERIC MODULATORS | RESEARCH TRIANGLE INSTITUTE | 2022-10-20 | — | — | US | disclosed |
| CN-115068587-A | Glycopeptide compound with antiviral activity and application thereof | 上海来益生物药物研究开发中心有限责任公司 | 2022-09-20 | — | — | CN | disclosed |
| US-20220257601-A1 | INHIBITORS OF PRC1 FOR TREATMENT OF CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-08-18 | — | — | US | disclosed |
| US-11407982-B2 | Transaminase mutant and use thereof | ASYMCHEM LIFE SCIENCE (TIANJIN) CO., LTD (CN) | 2022-08-09 | — | — | US | disclosed |
| CN-111886270-B | Polyurea copolymer, liquid crystal aligning agent, liquid crystal alignment film, and liquid crystal display element using same | 日产化学株式会社 | 2022-06-24 | — | — | CN | disclosed |
| CN-114645027-A | Aminotransferase mutant from bacillus megatherium and application thereof | 上海合全药物研发有限公司 | 2022-06-21 | — | — | CN | disclosed |
| CN-114560779-A | Synthesis method of mirabegron key intermediate | 杭州华东医药集团浙江华义制药有限公司 | 2022-05-31 | — | — | CN | disclosed |
| CN-114539182-A | Crystal transformation solvent and application thereof, and preparation method of mirabegron alpha crystal form | 威智医药有限公司 | 2022-05-27 | — | — | CN | disclosed |
| CN-114539084-A | Preparation method of mirabegron and intermediate thereof | 威智医药有限公司 | 2022-05-27 | — | — | CN | disclosed |
| CN-109384790-B | Fibroblast growth factor receptor inhibitors and uses thereof | 药捷安康(南京)科技股份有限公司 | 2022-05-10 | — | — | CN | disclosed |
| CN-113527311-B | FGFR4 inhibitor, composition and application thereof in preparation of medicines | 中南大学湘雅医院 | 2022-05-06 | — | — | CN | disclosed |
| EP-3990112-A1 | UREA DERIVATIVES AS CB1 ALLOSTERIC MODULATORS | RTI International (US) | 2022-05-04 | — | — | EP | disclosed |
| CN-110862359-B | Synthesis method of mirabegron | 苏州永健生物医药有限公司 | 2022-04-19 | — | — | CN | disclosed |
| WO-2022076663-A1 | ACETAMIDO-PHENYLTETRAZOLE DERIVATIVES AND METHODS OF USING THE SAME | ATHENEX, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| US-20220106312-A1 | ACETAMIDO-PHENYLTETRAZOLE DERIVATIVES AND METHODS OF USING THE SAME | Health Hope Pharma Limited (HK) | 2022-04-07 | — | — | US | disclosed |
| EP-3686188-B1 | PYRAZOLE DERIVATIVE, OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL (JP) | 2022-04-06 | — | — | EP | disclosed |
| US-11292878-B2 | Poly(L-lysine isolphthalamide) (PLP) polymers with hydrophobic pendant chains | Chen, Rongjun (GB) | 2022-04-05 | — | — | US | disclosed |
| CN-114269719-A | Urea derivatives as CB1 allosteric modulators | RTI国际 | 2022-04-01 | — | — | CN | disclosed |
| CN-110872234-B | Synthesis method of (1R) -2- [ [ [2- (4-nitrophenyl) ethyl ] amino ] methyl ] benzyl alcohol hydrochloride | 苏州永健生物医药有限公司 | 2022-03-04 | — | — | CN | disclosed |
| CN-111004135-B | Synthesis method of (1R) -2- [ [ [2- (4-aminophenyl) ethyl ] amino ] methyl ] benzyl alcohol | 苏州永健生物医药有限公司 | 2022-03-04 | — | — | CN | disclosed |
| CN-113773263-A | 4-amine substituted phthalazinone aurora kinase B inhibitor and preparation and application thereof | 兰州大学 | 2021-12-10 | — | — | CN | disclosed |
| CN-113527260-A | Compound capable of degrading STAT3 enzyme, preparation method and pharmaceutical application thereof | 四川海思科制药有限公司 | 2021-10-22 | — | — | CN | disclosed |
| CN-113527311-A | FGFR4 inhibitor, composition and application thereof in preparation of medicines | 中南大学湘雅医院 | 2021-10-22 | — | — | CN | disclosed |
| CN-109641878-B | DIPROVOCIM: effective TLR agonist | 斯克里普斯研究学院 | 2021-09-14 | — | — | CN | disclosed |
| CN-107043406-B | Compound, linker-drug, and ligand-drug conjugate | 财团法人工业技术研究院 | 2021-08-17 | — | — | CN | disclosed |
| CN-107709301-B | Pyrazole derivative or pharmacologically acceptable salt thereof | 橘生药品工业株式会社 | 2021-06-22 | — | — | CN | disclosed |
| US-11040959-B2 | Diprovocims: a new and potent class of TLR agonists | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-06-22 | — | — | US | disclosed |
| US-20210155594-A1 | HETEROCYCLIC DERIVATIVES AND USE THEREOF | C&C RESEARCH LABORATORIES (KR) | 2021-05-27 | — | — | US | disclosed |
| EP-3802495-A1 | HETEROCYCLIC DERIVATIVES AND USE THEREOF | C&C Research Laboratories (KR) | 2021-04-14 | — | — | EP | disclosed |
| EP-3484521-B1 | POLY(L-LYSINE ISOPHTHALAMIDE) (PLP) POLYMERS WITH HYDROPHOBIC PENDANT CHAINS | ALPHACELLS BIOTECHNOLOGIES LTD (GB) | 2021-04-07 | — | — | EP | disclosed |
| CN-107828751-B | Transaminase mutants and uses thereof | 凯莱英生命科学技术(天津)有限公司 | 2021-02-26 | — | — | CN | disclosed |
| US-20210024904-A1 | TRANSAMINASE MUTANT AND USE THEREOF | ASYMCHEM LIFE SCIENCE (TIANJIN) CO., LTD (CN) | 2021-01-28 | — | — | US | disclosed |
| CN-112204010-A | Heterocyclic derivatives and use thereof | C&C新药研究所 | 2021-01-08 | — | — | CN | disclosed |
| WO-2020264176-A1 | UREA DERIVATIVES AS CB1 ALLOSTERIC MODULATORS | RTI INTERNATIONAL (US) | 2020-12-30 | — | — | WO | disclosed |
| CN-112079724-A | Preparation method of dehydroxy mirabegron and intermediate thereof | 南京易亨制药有限公司 | 2020-12-15 | — | — | CN | disclosed |
| CN-108727212-B | Synthesis of mirabegron intermediate (R) -2-hydroxy-N- (4-nitrophenylethyl) -2-phenylacetamide | 安徽德信佳生物医药有限公司 | 2020-11-27 | — | — | CN | disclosed |
| EP-2740729-B1 | QUINAZOLINE DERIVATIVE, COMPOSITION HAVING THE DERIVATIVE, AND USE OF THE DERIVATIVE IN PREPARING MEDICAMENT | HANGZHOU MINSHENG INSTITUTES FOR PHARMA RES (CN) | 2020-11-25 | — | — | EP | disclosed |
| EP-3445758-B1 | DIPROVOCIMS: A NEW AND POTENT CLASS OF TLR AGONISTS | SCRIPPS RESEARCH INST (US) | 2020-11-04 | — | — | EP | disclosed |
| CN-111886270-A | Polyurea copolymer, liquid crystal aligning agent, liquid crystal alignment film, and liquid crystal display element using same | 日产化学株式会社 | 2020-11-03 | — | — | CN | disclosed |
| CN-111868618-A | Liquid crystal aligning agent, polymer for obtaining the same, liquid crystal alignment film, and liquid crystal display element using the same | 日产化学株式会社 | 2020-10-30 | — | — | CN | disclosed |
| CN-111868617-A | Liquid crystal aligning agent, polymer for obtaining the same, liquid crystal alignment film, and liquid crystal display element using the same | 日产化学株式会社 | 2020-10-30 | — | — | CN | disclosed |
| CN-109734712-B | Aryl or heteroaryl substituted pyrrolidine amide derivatives and uses thereof | 广东东阳光药业有限公司 | 2020-10-20 | — | — | CN | disclosed |
| US-20200308568-A1 | ALCOHOL STABLE ENZYMES | BIOHYBRID SOLUTIONS LLC | 2020-10-01 | — | — | US | disclosed |
| EP-3686188-A1 | PYRAZOLE DERIVATIVE, OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2020-07-29 | — | — | EP | disclosed |
| EP-3677674-A1 | TRANSAMINASE MUTANT AND USE THEREOF | Asymchem Life Science (Tianjin) Co., Ltd. (CN) | 2020-07-08 | — | — | EP | disclosed |
| CN-109776374-B | Acyl-substituted pyrrolidine amide derivatives and use thereof | 广东东阳光药业有限公司 | 2020-07-07 | — | — | CN | disclosed |
| US-20200207742-A1 | DIPROVOCIMS: A NEW AND POTENT CLASS OF TLR AGONISTS | THE SCRIPPS RESEARCH INSTITUTE | 2020-07-02 | — | — | US | disclosed |
| US-10683327-B2 | Compounds, linker-drugs and ligand-drug conjugates | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2020-06-16 | — | — | US | disclosed |
| CN-111263761-A | Novel polymer and diamine compound | 日产化学株式会社 | 2020-06-09 | — | — | CN | disclosed |
| CN-109761892-B | Amide derivatives substituted with nitrogen-containing heterocyclic group and use thereof | 广东东阳光药业有限公司 | 2020-06-05 | — | — | CN | disclosed |
| US-20200131431-A1 | CHEMICAL ADDITIVES AND SURFACTANT COMBINATIONS FOR FAVORABLE WETTABILITY ALTERATION AND IMPROVED HYDROCARBON RECOVERY FACTORS | ALCHEMY SCIENCES INC (US) | 2020-04-30 | — | — | US | disclosed |
| CN-109776373-B | Amide-substituted pyrrolidine amide derivatives and uses thereof | 广东东阳光药业有限公司 | 2020-04-21 | — | — | CN | disclosed |
| CN-111004135-A | Synthesis method of (1R) -2- [ [ [2- (4-aminophenyl) ethyl ] amino ] methyl ] benzyl alcohol | 苏州永健生物医药有限公司 | 2020-04-14 | — | — | CN | disclosed |
| CN-110950781-A | Novel diamine, polyamic acid, and polyimide | 日产化学工业株式会社 | 2020-04-03 | — | — | CN | disclosed |
| CN-110872234-A | Synthesis method of (1R) -2- [ [ [2- (4-nitrophenyl) ethyl ] amino ] methyl ] benzyl alcohol hydrochloride | 苏州永健生物医药有限公司 | 2020-03-10 | — | — | CN | disclosed |
| CN-110862359-A | Synthesis method of mirabegron | 苏州永健生物医药有限公司 | 2020-03-06 | — | — | CN | disclosed |
| CN-105659155-B | Liquid crystal aligning agent containing polyimide precursor and/or polyimide having thermally-releasable group | 日产化学工业株式会社 | 2020-01-21 | — | — | CN | disclosed |
| US-20190313641-A1 | ANTIMICROBIAL COMPOUND | PHYSICAL SCIENCES, INC. | 2019-10-17 | — | — | US | disclosed |
| CN-106938997-B | N- (4- replaces phenethyl) acetamides and application thereof | 华东理工大学 | 2019-10-11 | — | — | CN | disclosed |
| WO-2019182070-A1 | LIQUID CRYSTAL ALIGNING AGENT, POLYMER FOR OBTAINING SAME, LIQUID CRYSTAL ALIGNMENT FILM, AND LIQUID CRYSTAL DISPLAY ELEMENT USING SAME | 日産化学株式会社 | 2019-09-26 | — | — | WO | disclosed |
| WO-2019182071-A1 | LIQUID CRYSTAL ALIGNMENT AGENT, POLYMER FOR OBTAINING SAME, LIQUID CRYSTAL ALIGNMENT FILM, AND LIQUID CRYSTAL DISPLAY ELEMENT USING SAME | 日産化学株式会社 | 2019-09-26 | — | — | WO | disclosed |
| WO-2019182072-A1 | POLYUREA COPOLYMER, LIQUID CRYSTAL ALIGNMENT AGENT, LIQUID CRYSTAL ALIGNMENT FILM, AND LIQUID CRYSTAL DISPLAY ELEMENT USING SAME | 日産化学株式会社 | 2019-09-26 | — | — | WO | disclosed |
| US-20190248956-A1 | POLY(L-LYSINE ISOLPHTHALAMIDE) (PLP) POLYMERS WITH HYDROPHOBIC PENDANT CHAINS | IMPERIAL INNOVATIONS LIMITED (GB) | 2019-08-15 | — | — | US | disclosed |
| CN-110121362-A | Poly- (lysine isophtalamide) (PLP) polymer with hydrophobic side chain | 帝国理工大学创新有限公司 | 2019-08-13 | — | — | CN | disclosed |
| US-10336865-B2 | Liquid crystal aligning agent, liquid crystal alignment film and liquid crystal display device | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2019-07-02 | — | — | US | disclosed |
| EP-3484521-A1 | POLY(L-LYSINE ISOPHTHALAMIDE) (PLP) POLYMERS WITH HYDROPHOBIC PENDANT CHAINS | Imperial Innovations PLC (GB) | 2019-05-22 | — | — | EP | disclosed |
| CN-109776374-A | The pyrrolidine derivative and application thereof that acyl group replaces | 广东东阳光药业有限公司 | 2019-05-21 | — | — | CN | disclosed |
| CN-109776373-A | The pyrrolidine derivative and application thereof that amide replaces | 广东东阳光药业有限公司 | 2019-05-21 | — | — | CN | disclosed |
| CN-109761892-A | The amide derivatives and application thereof that nitrogen-containing heterocycle group replaces | 广东东阳光药业有限公司 | 2019-05-17 | — | — | CN | disclosed |
| US-10287251-B2 | Pyrazole derivative or pharmaceutically acceptable salt thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2019-05-14 | — | — | US | disclosed |
| CN-109734712-A | The pyrrolidine derivative and application thereof that aryl or heteroaryl replace | 广东东阳光药业有限公司 | 2019-05-10 | — | — | CN | disclosed |
| US-20190106459-A1 | COMPOUNDS, LINKER-DRUGS AND LIGAND-DRUG CONJUGATES | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2019-04-11 | — | — | US | disclosed |
| US-10233212-B2 | Compounds, linker-drugs and ligand-drug conjugates | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2019-03-19 | — | — | US | disclosed |
| EP-3436449-A1 | COMPOUNDS FOR THE INHIBITION OF CYCLOPHILINS AND USES THEREOF | Merck Patent GmbH (DE) | 2019-02-06 | — | — | EP | disclosed |
| EP-3165532-B1 | AURISTATIN DERIVATIVES, LINKER-DRUGS AND LIGAND-DRUG CONJUGATES | IND TECH RES INST (TW) | 2018-12-19 | — | — | EP | disclosed |
| US-10023530-B2 | Diamine, polyamic acid, and polyimide | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2018-07-17 | — | — | US | disclosed |
| US-10011772-B2 | Liquid crystal aligning agent, liquid crystal alignment film and liquid crystal display device | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2018-07-03 | — | — | US | disclosed |
| US-20180170879-A1 | PYRAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2018-06-21 | — | — | US | disclosed |
| US-9976086-B2 | Liquid crystal aligning agent containing polyimide precursor having thermally-leaving group and/or polyimide | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2018-05-22 | — | — | US | disclosed |
| US-9975902-B2 | Compounds for the inhibition of cyclophilins and uses thereof | MERCK PATENT GMBH (DE) | 2018-05-22 | — | — | US | disclosed |
| EP-3315492-A1 | PYRAZOLE DERIVATIVE, OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2018-05-02 | — | — | EP | disclosed |
| CN-107828751-A | Transaminase mutant and its application | 凯莱英生命科学技术(天津)有限公司 | 2018-03-23 | — | — | CN | disclosed |
| US-20180066007-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | BioVersys AG (CH) | 2018-03-08 | — | — | US | disclosed |
| US-20180016300-A1 | COMPOUNDS, LINKER-DRUGS AND LIGAND-DRUG CONJUGATES | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2018-01-18 | — | — | US | disclosed |
| WO-2018011580-A1 | POLY(L-LYSINE ISOPHTHALAMIDE) (PLP) POLYMERS WITH HYDROPHOBIC PENDANT CHAINS | IMPERIAL INNOVATIONS PLC (GB) | 2018-01-18 | — | — | WO | disclosed |
| EP-2857459-B1 | STABLE POLYMERIZABLE UV-ABSORBING COLORANT FOR INTRAOCULAR LENS | KOWA CO (JP) | 2017-12-27 | — | — | EP | disclosed |
| WO-2017173052-A1 | COMPOUNDS FOR THE INHIBITION OF CYCLOPHILINS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-10-05 | — | — | WO | disclosed |
| US-20170283427-A1 | COMPOUNDS FOR THE INHIBITION OF CYCLOPHILINS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-10-05 | — | — | US | disclosed |
| US-20170216335-A1 | METHODS, COMPOSITIONS, AND FORMULATIONS FOR PREVENTING OR REDUCING ADVERSE EFFECTS IN A PATIENT | PERICOR THERAPEUTICS INC (US) | 2017-08-03 | — | — | US | disclosed |
| CN-106938997-A | N (4 substitution phenethyl) acetamides and application thereof | 华东理工大学 | 2017-07-11 | — | — | CN | disclosed |
| EP-3165532-A2 | AURISTATIN DERIVATIVES, LINKER-DRUGS AND LIGAND-DRUG CONJUGATES | Industrial Technology Research Institute (TW) | 2017-05-10 | — | — | EP | disclosed |
| EP-3132796-A1 | METHODS, COMPOSITIONS, AND FORMULATIONS FOR PREVENTING OR REDUCING ADVERSE EFFECTS IN A PATIENT | Pericor Therapeutics, Inc. (US) | 2017-02-22 | — | — | EP | disclosed |
| US-9539274-B2 | Methods, compositions, and formulations for preventing or reducing adverse effects in a patient | PERICOR THERAPEUTICS, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-9499530-B2 | Quinazoline derivative, composition having the derivative, and use of the derivative in preparing medicament | HANGZHOU MINSHENG INSTITUTES FOR PHARMA RESEARCH (CN) | 2016-11-22 | — | — | US | disclosed |
| US-20160264867-A1 | LIQUID CRYSTAL ALIGNING AGENT CONTAINING POLYIMIDE PRECURSOR HAVING THERMALLY-LEAVING GROUP AND/OR POLYIMIDE | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-09-15 | — | — | US | disclosed |
| US-20160264520-A1 | NOVEL DIAMINE, POLYAMIC ACID, AND POLYIMIDE | NISSAN CHEMICAL INDUSTRIES. LTD. (JP) | 2016-09-15 | — | — | US | disclosed |
| US-20160244673-A1 | LIQUID CRYSTAL ALIGNING AGENT, LIQUID CRYSTAL ALIGNMENT FILM AND LIQUID CRYSTAL DISPLAY DEVICE | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-08-25 | — | — | US | disclosed |
| US-20160244566-A1 | LIQUID CRYSTAL ALIGNING AGENT, LIQUID CRYSTAL ALIGNMENT FILM AND LIQUID CRYSTAL DISPLAY DEVICE | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-08-25 | — | — | US | disclosed |
| US-9365501-B2 | Stable polymerizable UV-absorbing colorant for intraocular lens | KOWA COMPANY, LTD. (JP) | 2016-06-14 | — | — | US | disclosed |
| CN-105659155-A | Liquid crystal aligning agent containing polyimide precursor and/or polyimide having thermally-releasable group | 日产化学工业株式会社 | 2016-06-08 | — | — | CN | disclosed |
| CN-102911163-B | Quinazoline derivant, containing the composition of this derivative and the pharmaceutical applications of described derivative | Hangzhou Minsheng Pharmaceutical Co., Ltd. (CN) | 2016-05-11 | — | — | CN | disclosed |
| WO-2016024284-A2 | A PROCESS FOR THE PREPARATION OF MIRABEGRON AND ITS INTERMEDIATES | WANBURY LTD. (IN) | 2016-02-18 | — | — | WO | disclosed |
| WO-2015155664-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF 2-(2-AMINOTHIAZOL-4-YL)-N-[4-(2-[[(2R)-2-HYDROXY-2- PHENYLETHYL]AMINO]-ETHYL)PHENYL]ACETAMIDE | SUVEN LIFE SCIENCES LIMITED (IN) | 2015-10-15 | — | — | WO | disclosed |
| US-20150272978-A1 | METHODS, COMPOSITIONS, AND FORMULATIONS FOR PREVENTING OR REDUCING ADVERSE EFFECTS IN A PATIENT | PERICOR THERAPEUTICS, INC. | 2015-10-01 | — | — | US | disclosed |
| CN-103739523-B | Aligning agent for liquid crystal | NISSAN CHEMICAL INDUSTRIES CO., LTD. (JP) | 2015-08-05 | — | — | CN | disclosed |
| CN-104761471-A | Liquid crystal aligning agent | NISSAN CHEMICAL IND LTD | 2015-07-08 | — | — | CN | disclosed |
| CN-104744231-A | Method for splitting 2-hydracrylicacid racemate | TIANJIN INST PHARM RESEARCH | 2015-07-01 | — | — | CN | disclosed |
| US-20150158901-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | BioVersys AG (CH) | 2015-06-11 | — | — | US | disclosed |
| EP-2857459-A1 | STABLE POLYMERIZABLE UV-ABSORBING COLORANT FOR INTRAOCULAR LENS | Kowa Company Ltd. (JP) | 2015-04-08 | — | — | EP | disclosed |
| WO-2015044965-A1 | A PROCESS FOR PREPARATION OF MIRABEGRON AND ALPHA CRYSTALLINE FORM THEREOF | MEGAFINE PHARMA (P) LTD. (IN) | 2015-04-02 | — | — | WO | disclosed |
| US-20150094439-A1 | STABLE POLYMERIZABLE UV-ABSORBING COLORANT FOR INTRAOCULAR LENS | KOWA COMPANY, LTD. (JP) | 2015-04-02 | — | — | US | disclosed |
| US-8993527-B2 | Methods, compositions, and formulations for preventing or reducing adverse effects in a patient | PERICOR THERAPEUTICS, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20150080392-A1 | QUINAZOLINE DERIVATIVE, COMPOSITION HAVING THE DERIVATIVE, AND USE OF THE DERIVATIVE IN PREPARING MEDICAMENT | HANGZHOU MINSHENG PHARMACEUTICAL CO. LTD (CN) | 2015-03-19 | — | — | US | disclosed |
| CN-102971288-B | Novel process for producing bisaminophenylalkylurea | NISSAN CHEMICAL IND LTD | 2015-01-21 | — | — | CN | disclosed |
| CN-104284942-A | Stable polymerizable UV-absorbing colorant for intraocular lens | KOWA CO | 2015-01-14 | — | — | CN | disclosed |
| CN-104151170-A | 4-nitrophenethylamine hydrochloride and preparation method thereof | TIANJIN HEOWNS BIOCHEMISTRY TECHNOLOGY CO LTD | 2014-11-19 | — | — | CN | disclosed |
| CN-104151170-A | 4-nitrophenethylamine hydrochloride and preparation method thereof | TIANJIN HEOWNS BIOCHEMISTRY TECHNOLOGY CO LTD | 2014-11-19 | — | — | CN | disclosed |
| EP-2424532-B1 | COMPOUNDS FOR INDUCING CELLULAR APOPTOSIS | QUEEN MARY & WESTFIELD COLLEGE (GB) | 2014-09-24 | — | — | EP | disclosed |
| US-8841263-B2 | Macrocyclic compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-8835474-B2 | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient | ASTELLAS PHARMA INC. (JP) | 2014-09-16 | — | — | US | disclosed |
| WO-2014132270-A2 | PROCESS FOR THE PREPARATION OF 2-(2-AMINOTHIAZOL-4-YL)-N-[4-(2-{[(2R)-2-HYDROXY-2-PHENYL ETHYL]AMINO}ETHYL)PHENYL]ACETAMIDE MONOHYDROCHLORIDE, ITS INTERMEDIATES AND POLYMORPH THEREOF | MSN LABORATORIES LIMITED (IN) | 2014-09-04 | — | — | WO | disclosed |
| EP-2740729-A1 | QUINAZOLINE DERIVATIVE, COMPOSITION HAVING THE DERIVATIVE, AND USE OF THE DERIVATIVE IN PREPARING MEDICAMENT | Hangzhou Minsheng Institutes for Pharma Research (CN) | 2014-06-11 | — | — | EP | disclosed |
| US-8716302-B2 | Compounds for inducing cellular apoptosis | QUEEN MARY & WESTFIELD COLLEGE (GB) | 2014-05-06 | — | — | US | disclosed |
| US-RE44872-E1 | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient | ASTELLAS PHARMA INC. (JP) | 2014-04-29 | — | — | US | disclosed |
| CN-103739523-A | Liquid crystal aligning agent | NISSAN CHEMICAL IND LTD | 2014-04-23 | — | — | CN | disclosed |
| EP-2594273-A1 | Methods, compositions, and formulations for preventing or reducing adverse effects in a patient | Pericor Therapeutics, Inc. (US) | 2013-05-22 | — | — | EP | disclosed |
| EP-1971606-B1 | 2-PYRIMIDINYL PYRAZOLOPYRIDINE ERBB KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-04-24 | — | — | EP | disclosed |
| EP-2298752-B1 | Alpha-form or beta-form crystal of acetanilide derivative | ASTELLAS PHARMA INC (JP) | 2013-03-27 | — | — | EP | disclosed |
| CN-101039920-B | 2,6-substituted-4-monosubstitutedamino-pyrimidine as prostaglandin d2 receptor antagonists | AVENTIS PHARMA INC | 2013-03-20 | — | — | CN | disclosed |
| CN-102971288-A | Novel process for producing bisaminophenylalkylurea | NISSAN CHEMICAL IND LTD | 2013-03-13 | — | — | CN | disclosed |
| CN-102911163-A | Quinazoline derivatives, composition containing derivatives and pharmaceutical application of derivatives | Hangzhou minsheng pharmaceutical co ltd | 2013-02-06 | — | — | CN | disclosed |
| US-20120252747-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | SILICON VALLEY BANK | 2012-10-04 | — | — | US | disclosed |
| US-8247430-B2 | Substituted aryl-amine derivatives and methods of use | AMGEN INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-8247556-B2 | Method for preparing 6-substituted-7-aza-indoles | AMGEN INC. (US) | 2012-08-21 | — | — | US | disclosed |
| EP-1971604-B1 | PYRROLO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES | AMGEN INC (US) | 2012-08-01 | — | — | EP | disclosed |
| EP-1891019-B1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | AVENTIS PHARMA INC (US) | 2012-07-25 | — | — | EP | disclosed |
| US-8202843-B2 | Macrocyclic compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-8193183-B2 | 2,6-substituted-4-monosubstitutedamino-pyrimidine as prostaglandin D2 receptor antagonists | AVENTIS PHARMACEUTICALS INC. (US) | 2012-06-05 | — | — | US | disclosed |
| WO-2012058325-A1 | COMPOUNDS AND METHODS USEFUL FOR TREATMENT OF DISEASES MEDIATED BY HIF-1 | ONCOTHYREON INC. (US) | 2012-05-03 | — | — | WO | disclosed |
| US-20120101115-A1 | Compounds For Inducing Cellular Apoptosis | QUEEN MARY AND WESTFIELD COLLEGE (GB) | 2012-04-26 | — | — | US | disclosed |
| EP-2424532-A1 | COMPOUNDS FOR INDUCING CELLULAR APOPTOSIS | Queen Mary and Westfield College (GB) | 2012-03-07 | — | — | EP | disclosed |
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20110282031-A1 | A1 ADENOSINE RECEPTOR DIAGNOSTIC PROBES | WILSON CONSTANCE N (US) | 2011-11-17 | — | — | US | disclosed |
| US-20110230530-A1 | REMEDY FOR OVERACTIVE BLADDER COMPRISING ACETIC ACID ANILIDE DERIVATIVE AS THE ACTIVE INGREDIENT | ASTELLAS PHARMA INC. (JP) | 2011-09-22 | — | — | US | disclosed |
| US-7982049-B2 | (R)-2-(2-aminothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetanilide and a carrier; diabetes, anti-obesity and anti-hyperlipemia | ASTELLAS PHARMA INC. (JP) | 2011-07-19 | — | — | US | disclosed |
| US-7964730-B2 | Amino-substituted ethylamino β2 adrenergic receptor agonists | THERAVANCE, INC. (US) | 2011-06-21 | — | — | US | disclosed |
| EP-2298752-A1 | Alpha-form or beta-form crystal of acetanilide derivative | Astellas Pharma Inc. (JP) | 2011-03-23 | — | — | EP | disclosed |
| EP-1559427-B1 | REMEDY FOR OVERACTIVE BLADDER COMPRISING ACETIC ACID ANILIDE DERIVATIVE AS THE ACTIVE INGREDIENT | ASTELLAS PHARMA INC (JP) | 2011-03-09 | — | — | EP | disclosed |
| US-7902360-B2 | e.g. 3-[2-(4-aminophenyl)ethyl]-8-benzyl-7-(2-ethylamino)ethyl-1-propylxanthine; A1-adenosine receptor antagonist; antiallergen, antiinflammatory agent; AIDS and immune deficiency disorders, asthma; good water solubility | WILSON CONSTANCE N | 2011-03-08 | — | — | US | disclosed |
| WO-2011024078-A1 | 3 -OXOPIPERAZINIUM DERIVATIVES AS AGONISTS OF NERVE GROWTH FACTOR AND THEIR USE AS MEDICAMENTS | INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PII SUNYER (IDIBAPS) (ES) | 2011-03-03 | — | — | WO | disclosed |
| EP-2289882-A1 | 3-oxopiperazinium derivatives as agonists of nerve growth factor and their use as medicaments | Institut d'Investigacions Biomédiques August PI I Sunyer (ES) | 2011-03-02 | — | — | EP | disclosed |
| WO-2010125343-A1 | COMPOUNDS FOR INDUCING CELLULAR APOPTOSIS | QUEEN MARY AND WESTFIELD COLLEGE (GB) | 2010-11-04 | — | — | WO | disclosed |
| US-7812022-B2 | 2-pyrimidinyl pyrazolopyridine ErbB kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2010-10-12 | — | — | US | disclosed |
| US-7807673-B2 | 2-pyrimidinyl pyrazolopyridine ErbB kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2010-10-05 | — | — | US | disclosed |
| US-7750029-B2 | administering (R)-2-(2-aminothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide; treating urogenital disorders | ASTELLAS PHARMA INC. (JP) | 2010-07-06 | — | — | US | disclosed |
| EP-2139461-A2 | AMINO DERIVATIVES TO PREVENT NEPHROTOXICITY AND CANCER | Recepticon Aps (DK) | 2010-01-06 | — | — | EP | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-1773817-B1 | SUBSTITUTED ARYL-AMINE DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2009-08-26 | — | — | EP | disclosed |
| US-7576241-B2 | Derivatives of amidines, their preparation, their use as medicaments and the pharmaceutical compositions containing them | IPSEN PHARMA S.A.S. (FR) | 2009-08-18 | — | — | US | disclosed |
| EP-1863497-A4 | METHODS, COMPOSITIONS, AND FORMULATIONS FOR PREVENTING OR REDUCING ADVERSE EFFECTS IN A PATIENT | PERICOR THERAPEUTICS INC (US) | 2009-08-12 | — | — | EP | disclosed |
| US-20090149456-A1 | 2-Pyrimidinyl Pyrazolopyridine ErbB Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2009-06-11 | — | — | US | disclosed |
| US-20090143355-A1 | Substituted aryl-amine derivatives and methods of use | AMGEN INC. (US) | 2009-06-04 | — | — | US | disclosed |
| EP-1515972-B1 | AMIDE SUBSTITUTED XANTHINE DERIVATIVES WITH GLUCONEOGENESIS MODULATING ACTIVITY | HOFFMANN LA ROCHE (CH) | 2009-05-13 | — | — | EP | disclosed |
| EP-1828185-B1 | 2-PYRIMIDINYL PYRAZOLOPYRIDINE ERBB KINASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2009-05-06 | — | — | EP | disclosed |
| US-20090111850-A1 | Amino-Substituted Ethylamino Beta2 Adrenergic Receptor Agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-04-30 | — | — | US | disclosed |
| EP-1687257-B1 | AMINO-SUBSTITUTED ETHYLAMINO BETA2 ADRENERGIC RECEPTOR AGONISTS | THERAVANCE INC (US) | 2009-04-15 | — | — | EP | disclosed |
| US-7517889-B2 | 2,6-substituted-4-monosubstitutedamino-pyrimidine as prostaglandin D2 receptor antagonists | AVENTIS PHARMACEUTICALS, INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-20090093529-A1 | REMEDY FOR OVERACTIVE BLADDER COMPRISING ACETIC ACID ANILIDE DERIVATIVE AS THE ACTIVE INGREDIENT | ASTELLAS PHARMA INC. | 2009-04-09 | — | — | US | disclosed |
| US-7507748-B2 | Substituted aryl-amine derivatives and methods of use | AMGEN INC. (US) | 2009-03-24 | — | — | US | disclosed |
| US-20090068101-A9 | A1 Adenosine Receptor Antagonists | ENDACEA, INC. (US) | 2009-03-12 | — | — | US | disclosed |
| EP-1601649-A4 | A1 ADENOSINE RECEPTOR ANTAGONISTS | ENDACEA INC (US) | 2009-03-04 | — | — | EP | disclosed |
| CN-100465158-C | Amino-substituted ethylamino beta2-adrenergic receptor agonists | THERAVANCE INC (US) | 2009-03-04 | — | — | CN | disclosed |
| US-7473779-B2 | Derivatives of amidines, their preparation, their use as medicaments and the pharmaceutical compositions containing them | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2009-01-06 | — | — | US | disclosed |
| US-20080293705-A1 | A1 ADENOSINE RECEPTOR ANTAGONISTS | ENDACEA, INC. (US) | 2008-11-27 | — | — | US | disclosed |
| EP-1985620-A1 | 10a-AZALIDE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2008-10-29 | — | — | EP | disclosed |
| EP-1335902-B1 | HETEROARYLACRYLOYLAMINOALKYL-SUBSTITUTED BENZENESULFONAMIDE DERIVATIVES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-10-08 | — | — | EP | disclosed |
| WO-2008113364-A2 | AMINO DERIVATIVES TO PREVENT NEPHROTOXICITY AND CANCER | RECEPTICON APS (DK) | 2008-09-25 | — | — | WO | disclosed |
| EP-1971606-A2 | 2-PYRIMIDINYL PYRAZOLOPYRIDINE ERBB KINASE INHIBITORS | SmithKline Beecham Corporation (US) | 2008-09-24 | — | — | EP | disclosed |
| EP-1971604-A2 | PYRROLO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES | Amgen Inc. (US) | 2008-09-24 | — | — | EP | disclosed |
| US-7423041-B2 | e.g. 3-[2-(4-Aminophenyl)ethyl]-8-benzyl-1-propylxanthine; A1-adenosine receptor antagonist; antiallergen, antiinflammatory agent; AIDS and immune deficiency disorders, asthma; good water solubility | ENDACEA, INC. (US) | 2008-09-09 | — | — | US | disclosed |
| US-20080214633-A1 | Alpha-form or beta-form crystal of acetanilide derivative | ASTELLAS PHARMA INC. | 2008-09-04 | — | — | US | disclosed |
| EP-1636229-A4 | A1 ADENOSINE RECEPTOR ANTOGONISTS | ENDACEA INC (US) | 2008-07-30 | — | — | EP | disclosed |
| US-20080175891-A1 | METHODS, COMPOSITIONS, AND FORMULATIONS FOR PREVENTING OR REDUCING ADVERSE EFFECTS IN A PATIENT | PERICOR THERAPEUTICS, INC. | 2008-07-24 | — | — | US | disclosed |
| WO-2008086341-A1 | METHODS. COMPOSITIONS, AND FORMULATIONS FOR PREVENTING OR REDUCING ADVERSE EFFECTS IN A PATIENT | PERICOR THERAPEUTICS, INC. (US) | 2008-07-17 | — | — | WO | disclosed |
| US-7399863-B2 | Amino-substituted ethylamino β2 adrenergic receptor agonists | THERAVANCE, INC. (US) | 2008-07-15 | — | — | US | disclosed |
| EP-1932838-A2 | Beta-form crystal of acetanilide derivative | Astellas Pharma Inc. (JP) | 2008-06-18 | — | — | EP | disclosed |
| WO-2008039882-A1 | A COMBINATION OF NIACIN AND A PROSTAGLANDIN D2 RECEPTOR ANTAGONIST | SANOFI-AVENTIS U.S. LLC (US) | 2008-04-03 | — | — | WO | disclosed |
| US-7342117-B2 | (R)-2-(2-aminothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]-acetanilide; free base forms; stability; moisture resistance | ASTELLAS PHARMA INC. (JP) | 2008-03-11 | — | — | US | disclosed |
| WO-2008024634-A1 | PYRIMDINE COMPOUNDS USEFUL AS KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-02-28 | — | — | WO | disclosed |
| US-20080051395-A1 | 2-Pyrimidinyl Pyrazolopyridine Erbb Kinase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2008-02-28 | — | — | US | disclosed |
| EP-1891019-A2 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | Aventis Pharmaceuticals Inc. (US) | 2008-02-27 | — | — | EP | disclosed |
| US-20080045585-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | BioVersys AG (CH) | 2008-02-21 | — | — | US | disclosed |
| EP-1599477-B1 | SULFONAMIDE SUBSTITUTED XANTHINE DERIVATIVES FOR USE AS PEPCK INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-01-30 | — | — | EP | disclosed |
| EP-1330451-B1 | SUBSTITUTED BENZIMIDAZOL-2-ONES AS VASOPRESSIN RECEPTOR ANTAGONISTS AND NEUROPEPTIDE Y MODULATORS | ORTHO MCNEIL PHARM INC (US) | 2008-01-23 | — | — | EP | disclosed |
| CN-100361992-C | Sulfonamide substituted xanthine derivatives for use as PEPCK inhibitors | HOFFMANN LA ROCHE (CH) | 2008-01-16 | — | — | CN | disclosed |
| WO-2008005954-A2 | TRYPHOSTIN-ANALOGS FOR THE TREATMENT OF CELL PROLIFERATIVE DISEASES | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-01-10 | — | — | WO | disclosed |
| EP-1863497-A2 | METHODS, COMPOSITIONS, AND FORMULATIONS FOR PREVENTING OR REDUCING ADVERSE EFFECTS IN A PATIENT | Pericor Therapeutics, Inc. (US) | 2007-12-12 | — | — | EP | disclosed |
| US-20070282105-A1 | A1 ADENOSINE RECEPTOR ANTAGONISTS | ENDACEA, INC. (US) | 2007-12-06 | — | — | US | disclosed |
| US-20070274910-A1 | e.g. 3-[2-(2-Aminophenyl)ethyl]-8-benzyl-7-(2-methylamino)ethyl-1-propylxanthine; A1-adenosine receptor antagonist; antiallergen, antiinflammatory agent; AIDS and immune deficiency disorders, asthma; good water solubility | ENDACEA, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070265291-A1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-11-15 | — | — | US | disclosed |
| US-7285664-B2 | Heterocyclic or benzenic derivatives of lipoic acid, their preparation and their use as medicaments | S.C.R.A.S. SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (FR) | 2007-10-23 | — | — | US | disclosed |
| US-20070244131-A1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-10-18 | — | — | US | disclosed |
| EP-1828185-A2 | 2-PYRIMIDINYL PYRAZOLOPYRIDINE ERBB KINASE INHIBITORS | SmithKline Beecham Corporation (US) | 2007-09-05 | — | — | EP | disclosed |
| US-20070185171-A1 | Compounds and methods of use | AMGEN INC. | 2007-08-09 | — | — | US | disclosed |
| US-7247639-B2 | A1 adenosine receptor antagonists | ENDACEA, INC. (US) | 2007-07-24 | — | — | US | disclosed |
| US-20070161629-A1 | A1 Adenosine Receptor Antagonists | ENDACEA, INC. (US) | 2007-07-12 | — | — | US | disclosed |
| WO-2007067506-A2 | 2-PYRIMIDINYL PYRAZOLOPYRIDINE ERBB KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-14 | — | — | WO | disclosed |
| WO-2007048070-A2 | PYRROLO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES | AMGEN INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| EP-1773817-A1 | SUBSTITUTED ARYL-AMINE DERIVATIVES AND METHODS OF USE | Amgen Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| US-7202252-B2 | A1 adenosine receptor antagonists | ENDACEA, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-7186752-B2 | Derivatives of N-(iminomethyl)amines, their preparation, their use as medicaments and the pharmaceutical compositions containing them | SCRAS (FR) | 2007-03-06 | — | — | US | disclosed |
| US-20060293273-A1 | Methods, Compositions, and Formulations for Preventing or Reducing Adverse Effects in a Patient | PERICOR THERAPEUTICS, INC. | 2006-12-28 | — | — | US | disclosed |
| US-7148229-B2 | Sulfonamide substituted xanthine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2006-12-12 | — | — | US | disclosed |
| EP-1723159-A2 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | Rib-X Pharmaceuticals, Inc. (US) | 2006-11-22 | — | — | EP | disclosed |
| US-7135475-B2 | Antidiabetic agents | HOFFMANN-LA ROCHE INC. (US) | 2006-11-14 | — | — | US | disclosed |
| CN-1856465-A | Amino-substituted ethylamino beta2-adrenergic receptor agonists | THERAVANCE INC (US) | 2006-11-01 | — | — | CN | disclosed |
| WO-2006105167-A2 | METHODS, COMPOSITIONS, AND FORMULATIONS FOR PREVENTING OR REDUCING ADVERSE EFFECTS IN A PATIENT | PERICOR THERAPEUTICS, INC. (US) | 2006-10-05 | — | — | WO | disclosed |
| US-7109377-B2 | Synthesis of combinatorial libraries of compounds reminiscent of natural products | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2006-09-19 | — | — | US | disclosed |
| US-7105536-B2 | Compounds | SMITHKLINE BEECHAM PLC (GB) | 2006-09-12 | — | — | US | disclosed |
| EP-1687257-A2 | AMINO-SUBSTITUTED ETHYLAMINO &Bgr;2 ADRENERGIC RECEPTOR AGONISTS | Theravance, Inc. (US) | 2006-08-09 | — | — | EP | disclosed |
| WO-2006068826-A2 | 2-PYRIMIDINYL PYRAZOLOPYRIDINE ERBB KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-06-29 | — | — | WO | disclosed |
| US-20060115540-A1 | administering (R)-2-(2-aminothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide; treating urogenital disorders | ASTELLAS PHARMA INC. (JP) | 2006-06-01 | — | — | US | disclosed |
| WO-2006044732-A2 | 2, 6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| US-20060084667-A1 | New derivatives of amidines, their preparation, their use as medicaments and the pharmaceutical compositions containing them | IPSEN PHARMA S.A.S. (FR) | 2006-04-20 | — | — | US | disclosed |
| EP-1636229-A2 | A1 ADENOSINE RECEPTOR ANTOGONISTS | Endacea, Inc. (US) | 2006-03-22 | — | — | EP | disclosed |
| EP-1636230-A2 | A1 ADENOSINE RECEPTOR ANTAGONISTS | Endacea, Inc. (US) | 2006-03-22 | — | — | EP | disclosed |
| CN-1751044-A | Sulfonamide substituted xanthine derivatives for use as PEPCK inhibitors | HOFFMANN LA ROCHE (CH) | 2006-03-22 | — | — | CN | disclosed |
| CN-1243730-C | Cinnamoylaminoalkyl-substd. benzenesulfonamide derivs. | AVENTIS PHARMA GMBH (DE) | 2006-03-01 | — | — | CN | disclosed |
| US-20060040966-A1 | e.g. 2-(7-isoquinolinylamino)-N-(3-methyl-4-(1-methylethyl)phenyl)-3-pyridinecarboxamide; Vascular Endothelial Growth Factor antagonist; angiogenesis inhibitor; anticarcinogenic, antiinflammatory inhibitor; retinopathies, rheumatoid arthritis, asthma, atherosclerosis, endometriosis, neoplastic diseases | AMGEN INC. | 2006-02-23 | — | — | US | disclosed |
| WO-2006012374-A1 | SUBSTITUTED ARYL-AMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2006-02-02 | — | — | WO | disclosed |
| EP-1601649-A2 | A1 ADENOSINE RECEPTOR ANTAGONISTS | Endacea Inc. (US) | 2005-12-07 | — | — | EP | disclosed |
| EP-1599477-A1 | SULFONAMIDE SUBSTITUTED XANTHINE DERIVATIVES FOR USE AS PEPCK INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-30 | — | — | EP | disclosed |
| US-20050261269-A1 | New derivatives of amidines, their preparation, their use as medicaments and the pharmaceutical compositions containing them | SOCIETE DE CONSEILS DE RECHERCHES ET D' APPLICATIONS SCIENTIFIQUES (S.C.R.A.S) | 2005-11-24 | — | — | US | disclosed |
| US-20050256167-A1 | Preparation and use of imidazole derivatives for treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-11-17 | — | — | US | disclosed |
| EP-1367055-B1 | Isoquinolinyl carboxamides and their use as anticonvulsants | SMITHKLINE BEECHAM PLC (GB) | 2005-10-19 | — | — | EP | disclosed |
| US-20050227991-A1 | New heterocyclic or benzenic derivatives of lipoic acid, their preparation and their use as medicaments | IPSEN PHARMA S.A.S. (FR) | 2005-10-13 | — | — | US | disclosed |
| US-20050222124-A1 | Benzenesulfonamide derivatives as antipsychotic agents | GLAXO GROUP LIMITED (GB) | 2005-10-06 | — | — | US | disclosed |
| WO-2005085266-A2 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB-X PHARMACEUTICALS, INC. (US) | 2005-09-15 | — | — | WO | disclosed |
| US-20050197329-A1 | Derivatives of N-(iminomethyl)amines, their preparation, their use as medicaments and the pharmaceutical compositions containing them | SCRAS | 2005-09-08 | — | — | US | disclosed |
| US-6936715-B2 | Lipoic acid heterocyclic or benzene derivatives, preparation and use thereof as medicines | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (FR) | 2005-08-30 | — | — | US | disclosed |
| US-20050187226-A1 | A1 adenosine receptor antagonists | ENDACEA, INC. | 2005-08-25 | — | — | US | disclosed |
| EP-1559427-A1 | REMEDY FOR OVERACTIVE BLADDER COMPRISING ACETIC ACID ANILIDE DERIVATIVE AS THE ACTIVE INGREDIENT | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2005-08-03 | — | — | EP | disclosed |
| US-20050154011-A1 | Tetrahydroisoquinolnyl sulfamic acids | THE PROCTER & GAMBLE COMPANY | 2005-07-14 | — | — | US | disclosed |
| US-20050119258-A1 | A1 adenosine receptor antagonists | ENDACEA, INC. | 2005-06-02 | — | — | US | disclosed |
| US-20050113411-A1 | Amino-substituted ethylamino beta2 adrenergic receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2005-05-26 | — | — | US | disclosed |
| US-6887891-B2 | Derivatives of lipoic acid, their preparation, their use as medicaments and the pharmaceutical compositions containing them | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2005-05-03 | — | — | US | disclosed |
| WO-2005030678-A2 | AMINO-SUBSTITUTED ETHYLAMINO β2 ADRENERGIC RECEPTOR AGONISTS | THERAVANCE, INC. (US) | 2005-04-07 | — | — | WO | disclosed |
| EP-1515972-A1 | AMIDE SUBSTITUTED XANTHINE DERIVATIVES WITH GLUCONEOGENESIS MODULATING ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-23 | — | — | EP | disclosed |
| EP-1345892-B1 | ACYLAMINOALKYL-SUBSTITUTED BENZENESULFONAMIDE DERIVATIVES | AVENTIS PHARMA GMBH (DE) | 2005-03-09 | — | — | EP | disclosed |
| US-20050032793-A1 | 2-amino-benzoxazinones for the treatment of viral infections | G.D. SEARLE & CO. (US) | 2005-02-10 | — | — | US | disclosed |
| WO-2005009343-A2 | A1 ADENOSINE RECEPTOR ANTOGONISTS | ENDACEA, INC. (US) | 2005-02-03 | — | — | WO | disclosed |
| US-20050027009-A1 | New derivatives of N-(iminomethyl)amines, their preparation, their use as medicaments and the pharmaceutical compositions containing them | SOCIETE DE CONSEILS DE RECHERCHES D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) | 2005-02-03 | — | — | US | disclosed |
| US-6841560-B2 | Substituted isoquinoline derivatives and their use as anticonvulsants | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-01-11 | — | — | US | disclosed |
| US-20050004190-A1 | Alpha-form or beta-form crystal of acetanilide derivative | ASTELLAS PHARMA INC. (JP) | 2005-01-06 | — | — | US | disclosed |
| CN-1183116-C | Substituted isoquinoline derivatives, pharmaceutical composition containing same, preparation method and application thereof | ʷ��˿�������ȳ�ķ����˾ | 2005-01-05 | — | — | CN | disclosed |
| WO-2004110379-A2 | A1 ADENOSINE RECEPTOR ANTAGONISTS | ENDACEA, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
| EP-1474399-A1 | BENZENESULFONAMIDE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2004-11-10 | — | — | EP | disclosed |
| EP-0798292-B1 | ANILINE DERIVATIVES HAVING NITROGEN MONOXIDE SYNTHASE INHIBITORY ACTIVITY | CHUGAI SEIYAKUKABUSHIKI KAISHA (JP) | 2004-11-03 | — | — | EP | disclosed |
| US-6809090-B2 | NITROGEN MONOXIDE SYNTHASE AND/OR LIPIDIC PEROXIDATION INHIBITORS | IPSEN PHARMA S.A.S. (FR) | 2004-10-26 | — | — | US | disclosed |
| US-20040209912-A1 | Substituted isoquinoline derivatives and their use as anticonvulsants | SMITHKLINE BEECHAM P.L.C. | 2004-10-21 | — | — | US | disclosed |
| US-20040192708-A1 | Sulfonamide substituted xanthine derivatives | DUNTEN PETER W (US) | 2004-09-30 | — | — | US | disclosed |
| WO-2004074256-A1 | TETRAHYDROISOQUINOLINYL SULFAMIC ACIDS | THE PROCTER & GAMBLE COMPANY (US) | 2004-09-02 | — | — | WO | disclosed |
| WO-2004074238-A1 | PHENETHYLAMINO SULFAMIC ACIDS | THE PROCTER & GAMBLE COMPANY (US) | 2004-09-02 | — | — | WO | disclosed |
| WO-2004074247-A2 | A1 ADENOSINE RECEPTOR ANTAGONISTS | ENDACEA, INC. (US) | 2004-09-02 | — | — | WO | disclosed |
| WO-2004074288-A1 | SULFONAMIDE SUBSTITUTED XANTHINE DERIVATIVES FOR USE AS PEPCK INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-09-02 | — | — | WO | disclosed |
| US-20040167183-A1 | Phenethylamino sulfamic acids | THE PROCTER & GAMBLE COMPANY | 2004-08-26 | — | — | US | disclosed |
| US-6770657-B2 | ARYL OR HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINE DERIVATES POSSESS ANTI-CONVULSANT ACTIVITY AND ARE THEREFORE BELIEVED TO BE USEFUL IN THE TREATMENT AND/OR PREVENTION OF MANY DISEASES | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-08-03 | — | — | US | disclosed |
| EP-1440969-A1 | ALPHA-FORM OR BETA-FORM CRYSTAL OF ACETANILIDE DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2004-07-28 | — | — | EP | disclosed |
| CN-1515550-A | Thrombosis resisting preparation | — | 2004-07-28 | — | — | CN | disclosed |
| US-20040142964-A1 | Novel compounds | SMITHKLINE BEECHAM P.L.C. | 2004-07-22 | — | — | US | disclosed |
| US-20040097494-A1 | New derivatives of N-(iminomethy)amines, their preparation, their use as medicaments and the pharmaceutical compositions containing them | SOCIETE DE CONSEILS DE RECHERCHES D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) | 2004-05-20 | — | — | US | disclosed |
| EP-1028111-B1 | AMIDE DERIVATIVES OR SALTS THEREOF | YAMANOUCHI PHARMA CO LTD (JP) | 2004-05-12 | — | — | EP | disclosed |
| EP-0737680-B1 | (Phenylalkylaminoalkyloxyl)-hetero-aryl compounds, processes and intermediates for their preparation and medicaments containing these compounds | SOLVAY PHARM GMBH (DE) | 2004-03-03 | — | — | EP | disclosed |
| EP-1042296-B1 | SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS | SMITHKLINE BEECHAM PLC (GB) | 2004-02-25 | — | — | EP | disclosed |
| EP-1200409-B1 | SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS | SMITHKLINE BEECHAM PLC (GB) | 2004-02-25 | — | — | EP | disclosed |
| US-20040019084-A1 | New derivatives of lipoic acid, their preparation, their use as medicaments and the pharmaceutical compositions containing them | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATION SCIENTIFIQUES (S.C.R.A.S) | 2004-01-29 | — | — | US | disclosed |
| US-6683077-B2 | 4H-3,1-BENZOXAZIN-4-ONE COMPOUNDS OF GIVEN FORMULA; HERPES INFECTIONS; ASSEMBLIN PROTEASE INHIBITORS | G.D. SEARLE & CO. | 2004-01-27 | — | — | US | disclosed |
| US-20040014766-A1 | Amide substituted xanthine derivatives | HOFFMANN-LA ROCHE INC. | 2004-01-22 | — | — | US | disclosed |
| WO-2003106459-A1 | AMIDE SUBSTITUTED XANTHINE DERIVATIVES WITH GLUCONEOGENESIS MODULATING ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2003-12-24 | — | — | WO | disclosed |
| EP-0934276-B1 | ANTHRANILIC ACID DERIVATIVES AS MULTI DRUG RESISTANCE MODULATORS | XENOVA LTD (GB) | 2003-12-17 | — | — | EP | disclosed |
| EP-1100775-B1 | 2,5-SUBSTITUTED BENZOLSULFONYLUREAS AND THIOUREAS, METHODS FOR THE PRODUCTION THEREOF, USE THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME | AVENTIS PHARMA GMBH (DE) | 2003-12-17 | — | — | EP | disclosed |
| EP-1367055-A1 | Isoquinolinyl carboxamides and their use as anticonvulsants | SMITHKLINE BEECHAM PLC (GB) | 2003-12-03 | — | — | EP | disclosed |
| US-6653478-B2 | Psychological disorders; hypotensive agents | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-11-25 | — | — | US | disclosed |
| US-6653312-B1 | Such as 3-((3-((amino(2-thienyl)methylideneamino)-benzyl)-amino)-N-(1- methyl-2,3-dihydro-1H-indol-5-yl)propanamide; NO-synthase enzyme inhibitors | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2003-11-25 | — | — | US | disclosed |
| EP-1361212-A1 | Peptide derivatives as antithrombotic agents | AstraZeneca AB (SE) | 2003-11-12 | — | — | EP | disclosed |
| EP-1077935-B1 | PHENYLSULFONAMIDE-PHENYLETHYLAMINES USEFUL AS DOPAMINE RECEPTORS | UPJOHN CO (US) | 2003-10-29 | — | — | EP | disclosed |
| EP-1183236-B1 | CINNAMOYLAMINOALKYL-SUBSTITUTED BENZENESULFONAMIDE DERIVATIVES | AVENTIS PHARMA GMBH (DE) | 2003-10-22 | — | — | EP | disclosed |
| EP-1345892-A2 | ACYLAMINOALKYL-SUBSTITUTED BENZENESULFONAMIDE DERIVATIVES | Aventis Pharma Deutschland GmbH (DE) | 2003-09-24 | — | — | EP | disclosed |
| EP-0672658-B1 | Antithrombotic agents | ASTRAZENECA AB (SE) | 2003-09-17 | — | — | EP | disclosed |
| US-6620840-B1 | Nitric oxide synthase inhibitors | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2003-09-16 | — | — | US | disclosed |
| US-20030162799-A1 | Carbocyclic oxo, carboxy amines such as 3-(4-(3,5-Dichloro-4-pyridylcarboxamido)phenyl)-2-(2-propylamino-3,4 -dioxocyclobut-1-enyl)amino)propanoic acid, used as integrin antagonists; antiinflammatory agents | CELLTECH R&D LIMITED (GB) | 2003-08-28 | — | — | US | disclosed |
| WO-2003068752-A1 | BENZENESULFONAMIDE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
| EP-1335902-A1 | HETEROARYLACRYLOYLAMINOALKYL-SUBSTITUTED BENZENESULFONAMIDE DERIVATIVES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | Aventis Pharma Deutschland GmbH (DE) | 2003-08-20 | — | — | EP | disclosed |
| US-6605637-B1 | Nitrogen monoxide synthase inhibitors; such as n-(4-(((2-thienyl)(imino)methyl)amino)phenyl)-1,2-dithiolane-3-pentamide | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2003-08-12 | — | — | US | disclosed |
| US-6605618-B2 | Antidiabetic agents; hypoglycemic agents; anticholesterol agents; side effect reduction | WYETH | 2003-08-12 | — | — | US | disclosed |
| US-6602864-B1 | Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-08-05 | — | — | US | disclosed |
| US-20030144320-A1 | For treatment and/or prevention of anxiety, mania, depression, panic disorders, nerve sustem disorders | SMITHKLINE BEECHAM P.L.C. | 2003-07-31 | — | — | US | disclosed |
| EP-1330451-A2 | SUBSTITUTED BENZIMIDAZOL-2-ONES AS VASOPRESSIN RECEPTOR ANTAGONISTS AND NEUROPEPTIDE Y MODULATORS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-07-30 | — | — | EP | disclosed |
| EP-1237548-A4 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2003-07-23 | — | — | EP | disclosed |
| US-20030105107-A1 | Novel lipoic acid heterocyclic or benzene derivatives, preparation and use thereof as medicines | IPSEN PHARMA S.A.S. (FR) | 2003-06-05 | — | — | US | disclosed |
| US-20030082830-A1 | Synthesis of combinatorial libraries of compounds reminiscent of natural products | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-05-01 | — | — | US | disclosed |
| US-20030073842-A1 | Novel substituted benzimidazol-2-ones as vasopressin receptor antagonists and neuropeptide Y modulators | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-04-17 | — | — | US | disclosed |
| EP-0972769-B1 | NOVEL AMIDE DERIVATIVES AND MEDICINAL COMPOSITIONS THEREOF | YAMANOUCHI PHARMA CO LTD (JP) | 2003-04-16 | — | — | EP | disclosed |
| US-6534546-B1 | Guanidine- or isothioureido-N-derived anilines; brain, nervous system, and neurodegenerative disorders | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-03-18 | — | — | US | disclosed |
| US-20030036551-A1 | Novel compounds | SMITHKLINE BEECHAM P.L.C. | 2003-02-20 | — | — | US | disclosed |
| US-6518283-B1 | To modify integrin function in such a way as to beneficially modulate cell adhesion | CELLTECH R&D LIMITED (GB) | 2003-02-11 | — | — | US | disclosed |
| US-20030022895-A1 | 2-Amino-benzoxazinones for the treatment of viral infections | G.D. SEARLE & CO. | 2003-01-30 | — | — | US | disclosed |
| US-6511989-B2 | For therapy of vagal dysfunction in the heart, improving cardiac function, therapy of person susceptible to cardiac death | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-01-28 | — | — | US | disclosed |
| US-20030018045-A1 | Heterocyclic beta-3 adrenergic receptor agonists | WYETH (US) | 2003-01-23 | — | — | US | disclosed |
| EP-0713483-B1 | AMIDINE DERIVATIVES WITH NITRIC OXIDE SYNTHETASE ACTIVITIES | ASTRAZENECA AB (SE) | 2003-01-15 | — | — | EP | disclosed |
| CN-1098841-C | Novel amide derivatives and pharmaceutical compositions thereof | YAMANOUCHI PHARMA CO LTD (JP) | 2003-01-15 | — | — | CN | disclosed |
| US-6492388-B1 | SUCH AS N-(5-CHLORO-1,2,3,4-TETRAHYDROISOQUINOLIN-7-YL)-4-ETHOXYBENZAMIDE | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-12-10 | — | — | US | disclosed |
| US-6482822-B1 | N-(iminomethyl)amines derivatives, their preparation, their use as medicines and compositions containing them | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2002-11-19 | — | — | US | disclosed |
| US-6472413-B2 | FOR THERAPY OF VAGAL DYSFUNCTION IN THE HEART, IMPROVING CARDIAC FUNCTION, THERAPY OF PERSON SUSCEPTIBLE TO CARDIAC DEATH | ADVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-10-29 | — | — | US | disclosed |
| US-6458817-B1 | AROMATIC SUBSTITUTED SUFURE OR SULFOXIDE OR SULFONE DERIVATIVES CONTAINING SECONDAY AMINE AND HYDROXY GROUPS ARE USEFUL IN TREATNG METABOLIC DISORDERS MEDIATED BY INSULIN RESISTANCE OR HYPERGLYCEMIA IN MAMMALS | WYETH | 2002-10-01 | — | — | US | disclosed |
| EP-0944386-B1 | SULFONIC ACID OR SULFONYLAMINO N-(HETEROARALKYL)-AZAHETEROCYCLYLAMIDE COMPOUNDS | AVENTIS PHARMA INC (US) | 2002-09-18 | — | — | EP | disclosed |
| US-6451814-B1 | SUBSTITUTED 4-((4-AMINO-5-HYDROXYPHENYL)-OXY-)PIPERIDINE ANALOGS; METABOLIC DISORDERS; ANTIDIABETIC AGENTS; ATHERO-SCLEROSIS, GASTROINTESTINAL DISORDERS, GLAUCOMA, NEUROGENETIC INFLAMMATION, OCULAR HYPERTENSION AND FREQUENT URINATION | WYETH | 2002-09-17 | — | — | US | disclosed |
| EP-1237548-A1 | IL-8 RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2002-09-11 | — | — | EP | disclosed |
| US-6448443-B1 | GENERATED FROM DIVERSIFIABLE SCAFFOLDS SYNTHESIZED FROM THE PYRIDINE-BASED TEMPLATE ISONICOTINAMIDE; ALSO PROVIDES A NOVEL ORTHO-NITROBENZYL PHOTOLINKER; SYNTHESIZED FROM A SHIKIMIC ACID BASED EPOXYOL TEMPLATE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2002-09-10 | — | — | US | disclosed |
| US-20020123494-A1 | Acylaminoalkyl-substituted benzenesulfonamide derivatives, their preparation, their use and pharmaceutical preparations comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-09-05 | — | — | US | disclosed |
| US-20020123495-A1 | Heteroarylacryloylaminoalkyl-substituted benzenesulfonamide derivatives, their preparation, their use and pharmaceutical preparations comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-09-05 | — | — | US | disclosed |
| CN-1360571-A | Cinnamoylaminoalkyl-substd. benzenesulfonamide derivs. | AVENTIS PHARMA GMBH (DE) | 2002-07-24 | — | — | CN | disclosed |
| WO-2002055514-A2 | SUBSTITUTED BENZIMIDAZOL-2-ONES AS VASOPRESSIN RECEPTOR ANTAGONISTS AND NEUROPEPTIDE Y MODULATORS | ORTHO MCNEIL PHARM INC (US) | 2002-07-18 | — | — | WO | disclosed |
| US-6410573-B1 | CARDIOVASCULAR DISEASES; POTASSIUM CHANNEL MODULATOR | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-06-25 | — | — | US | disclosed |
| US-6395730-B1 | CARDIOVASCULAR DISORDERS | ICAGEN, INC. | 2002-05-28 | — | — | US | disclosed |
| WO-2002036556-A2 | ACYLAMINOALKYL-SUBSTITUTED BENZENESULFONAMIDE DERIVATIVES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-05-10 | — | — | WO | disclosed |
| WO-2002036565-A1 | HETEROARYLACRYLOYLAMINOALKYL-SUBSTITUTED BENZENESULFONAMIDE DERIVATIVES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-05-10 | — | — | WO | disclosed |
| EP-1200409-A2 | SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS | SMITHKLINE BEECHAM PLC (GB) | 2002-05-02 | — | — | EP | disclosed |
| US-6380189-B1 | FOR TREATING HERPES-RELATED DISORDERS | G.D. SEARLE & CO. | 2002-04-30 | — | — | US | disclosed |
| US-20020040023-A1 | Substituted arylsulfides, arylsulfoxides and arylsulfones as beta-3 adrenergic receptor agonists | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-04-04 | — | — | US | disclosed |
| US-20020028832-A1 | Heterocyclic beta-3 adrenergic receptor agonists | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-03-07 | — | — | US | disclosed |
| EP-1183236-A1 | CINNAMOYLAMINOALKYL-SUBSTITUTED BENZENESULFONAMIDE DERIVATIVES | Aventis Pharma Deutschland GmbH (DE) | 2002-03-06 | — | — | EP | disclosed |
| EP-1181266-A1 | SQUARIC ACID DERIVATIVES AS CELL ADHESION MOLECULES | Celltech R&D Limited (GB) | 2002-02-27 | — | — | EP | disclosed |
| US-6350778-B1 | CARDIOVASCULAR DISORDERS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-02-26 | — | — | US | disclosed |
| US-6346532-B1 | ANTIDIABETIC, ANTILIPEMIC, AND HYPOGLYCEMIC AGENTS; ADRENERGIC STIMULANTS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2002-02-12 | — | — | US | disclosed |
| US-20020013310-A1 | Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds | AVENTIS PHARMACEUTICALS PRODUCTS INC. | 2002-01-31 | — | — | US | disclosed |
| WO-2002006229-A2 | HETEROCYCLIC BETA-3 ADRENERGIC RECEPTOR AGONISTS | WYETH (US) | 2002-01-24 | — | — | WO | disclosed |
| WO-2002006250-A1 | SUBSTITUTED ARYLSULFIDES, ARYLSULFOXIDES AND ARYLSULFONES AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | WYETH (US) | 2002-01-24 | — | — | WO | disclosed |
| EP-1086099-A4 | SULFONIC ACID OR SULFONYLAMINO N-(HETEROARALKYL)-AZAHETEROCYCLYLAMIDE COMPOUNDS | AVENTIS PHARM PROD INC (US) | 2002-01-02 | — | — | EP | disclosed |
| EP-0781126-B1 | DERIVATIVES OF 2-AMINO-1,2,3,4-TETRAHYDRO-NAPHTHALENE ACTIVE ON THE CARDIOVASCULAR SYSTEM | ZAMBON SPA (IT) | 2001-12-12 | — | — | EP | disclosed |
| EP-0828721-B1 | 2-AMINO-BENZOXAZINONES FOR THE TREATMENT OF VIRAL INFECTIONS | SEARLE & CO (US) | 2001-11-14 | — | — | EP | disclosed |
| US-20010025045-A1 | Substituted isoquinoline derivatives and their use as anticonvulsants | SMITHKLINE BEECHAM P.L.C. | 2001-09-27 | — | — | US | disclosed |
| US-6281227-B1 | INHIBITORS OF THE ACTIVITY OF FACTOR XA. | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-08-28 | — | — | US | disclosed |
| US-20010016657-A1 | Substituted isoquinoline derivatives and their use as anticonvulsants | SMITHKLINE BEECHAM P.L.C. | 2001-08-23 | — | — | US | disclosed |
| US-6274594-B1 | ANTICONVULSANTS, ANALGESICS; NERUOPATHIC, CANCER AND DENTAL PAIN; | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-08-14 | — | — | US | disclosed |
| EP-1122245-A2 | 2-Amino-benzoxazinones for the treatment of viral infections | G.D. Searle & Co. (US) | 2001-08-08 | — | — | EP | disclosed |
| US-6263699-B1 | INSERTING A PIN EXTENDING INTO THE AQUEOUS PHASE, COOLING THE TWO PHASE MIXTURE TO SOLIDIFICATION AND REMOVAL OF THE PIN WITH THE SOLIDIFIED AQUEOUS ATTACHED | RADLEYS COMBI-CHEM, LTD. (GB) | 2001-07-24 | — | — | US | disclosed |
| US-6248754-B1 | PSYCHOLOGICAL DISORDERS | SMITHKLINE BEECHAM, P.L.C. (GB) | 2001-06-19 | — | — | US | disclosed |
| WO-2001039759-A2 | SULFONIC ACID OR SULFONYLAMINO N-(HETEROARALKYL)-AZAHETEROCYCLYLAMIDE COMPOUNDS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-06-07 | — | — | WO | disclosed |
| WO-2001034141-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-05-17 | — | — | WO | disclosed |
| US-6218393-B1 | IN THERAPY OF MULTIDRUG RESISTANT CANCERS, FOR EXAMPLE TO POTENTIATE CYTOTOXICITY OF CANCER DRUG | XENOVA LIMITED (GB) | 2001-04-17 | — | — | US | disclosed |
| EP-0944386-A4 | SULFONIC ACID OR SULFONYLAMINO N-(HETEROARALKYL)-AZAHETEROCYCLYLAMIDE COMPOUNDS | AVENTIS PHARM PROD INC (US) | 2001-04-11 | — | — | EP | disclosed |
| EP-1086099-A1 | SULFONIC ACID OR SULFONYLAMINO N-(HETEROARALKYL)-AZAHETEROCYCLYLAMIDE COMPOUNDS | Aventis Pharmaceuticals Products Inc. (US) | 2001-03-28 | — | — | EP | disclosed |
| EP-1082315-A1 | POTASSIUM CHANNEL INHIBITORS | Icagen, Inc. (US) | 2001-03-14 | — | — | EP | disclosed |
| EP-1077935-A1 | PHENYLSULFONAMIDE-PHENYLETHYLAMINES USEFUL AS DOPAMINE RECEPTORS | PHARMACIA & UPJOHN COMPANY (US) | 2001-02-28 | — | — | EP | disclosed |
| US-6177454-B1 | ANTIDIABETIC AGENTS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2001-01-23 | — | — | US | disclosed |
| EP-0915847-A4 | SUBSTITUTED SULFONAMIDES AS SELECTIVE BETA3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY | MERCK & CO INC (US) | 2001-01-17 | — | — | EP | disclosed |
| US-6174908-B1 | TREATING DISEASE, CONDITION, OR DISORDER WHICH RESPONDS TO INHIBITION OF POTASSIUM CHANNEL FUNCTION BY ADMINISTERING THIAZOLIDONE OR METATHIAZONONE COMPOUND, ITS SALT, AMIDE, ESTER, COMPLEX, CHELATE, HYDRATE, STEREOISOMER, METABOLITE | ICAGEN, INC. | 2001-01-16 | — | — | US | disclosed |
| WO-2001002366-A2 | SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS INTICONVULSANTS | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-01-11 | — | — | WO | disclosed |
| WO-2000073260-A1 | SQUARIC ACID DERIVATIVES AS CELL ADHESION MOLECULES | CELLTECH R&D LIMITED (GB) | 2000-12-07 | — | — | WO | disclosed |
| WO-2000071513-A1 | CINNAMOYLAMINOALKYL-SUBSTITUTED BENZENESULFONAMIDE DERIVATIVES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-11-30 | — | — | WO | disclosed |
| EP-1042296-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS | SMITHKLINE BEECHAM PLC (GB) | 2000-10-11 | — | — | EP | disclosed |
| EP-1032570-A1 | ISOQUINOLINE DERIVATIVES AND THEIR THERAPEUTICAL USE | SMITHKLINE BEECHAM PLC (GB) | 2000-09-06 | — | — | EP | disclosed |
| EP-0882066-B1 | PEPTIDE DERIVATIVES | ZENECA LTD (GB) | 2000-09-06 | — | — | EP | disclosed |
| US-6110934-A | Substituted benzamide derivatives and their use as anticonvulsants | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-08-29 | — | — | US | disclosed |
| EP-1028111-A1 | AMIDE DERIVATIVES OR SALTS THEREOF | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2000-08-16 | — | — | EP | disclosed |
| US-6103766-A | SUBSTITUTED OR UNSUBSTITUTED PHENYLSULFONAMIDE-PHENYLAMINE DERIVATIVES USEFUL FOR TREATING THE DISORDERS RELATED TO CENTRAL NERVOUS SYSTEM | PHARMACIA & UPJOHN COMPANY (US) | 2000-08-15 | — | — | US | disclosed |
| EP-1025087-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS | SMITHKLINE BEECHAM PLC (GB) | 2000-08-09 | — | — | EP | disclosed |
| US-6087336-A | ANTIINFLAMMATORY AGENT TREATING RHEUMATOID ARTHRITIS | ZENECA LIMITED (GB) | 2000-07-11 | — | — | US | disclosed |
| EP-1005459-A1 | SUBSTITUTED ISOQUINOLINES AS ANTICONVULSIVANTS | SMITHKLINE BEECHAM PLC (GB) | 2000-06-07 | — | — | EP | disclosed |
| CN-1255124-A | Substituted isoquinoline derivatives and their use as anticonulsants | SMITHKLINE BEECHAM PLC (GB) | 2000-05-31 | — | — | CN | disclosed |
| WO-2000006525-A9 | SYNTHESIS OF COMBINATORIAL LIBRARIES OF COMPOUNDS REMINISCENT OF NATURAL PRODUCTS | HARVARD COLLEGE (US) | 2000-04-20 | — | — | WO | disclosed |
| US-6048884-A | ANTIDIABETIC AGENTS; HYPOGLYCEMIC AGENTS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2000-04-11 | — | — | US | disclosed |
| EP-0983110-A1 | SEPARATION OF A TWO PHASE MIXTURE BY FREEZING | Radleys Combi-Chem Limited (GB) | 2000-03-08 | — | — | EP | disclosed |
| US-6030985-A | Amidine derivatives with nitric oxide synthetase activities | ASTRA AKTIEBOLAG (SE) | 2000-02-29 | — | — | US | disclosed |
| WO-2000007993-A1 | SUBSTITUTED ISOQUINOLEINES AND THEIR USE AS ANTICONVULSIVANTS | SMITHKLINE BEECHAM PLC (GB) | 2000-02-17 | — | — | WO | disclosed |
| WO-2000006525-A2 | SYNTHESIS OF COMBINATORIAL LIBRARIES OF COMPOUNDS REMINISCENT OF NATURAL PRODUCTS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2000-02-10 | — | — | WO | disclosed |
| CN-1244193-A | Novel amide derivatives and medicinal compositions thereof | YAMANOUCHI PHARMA CO LTD (JP) | 2000-02-09 | — | — | CN | disclosed |
| EP-0975593-A1 | INDOLE DERIVATIVES HAVING COMBINED 5HT1A, 5HT1B AND 5HT1D RECEPTOR ANTAGONIST ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 2000-02-02 | — | — | EP | disclosed |
| EP-0972769-A1 | NOVEL AMIDE DERIVATIVES AND MEDICINAL COMPOSITIONS THEREOF | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2000-01-19 | — | — | EP | disclosed |
| EP-0968190-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS | SMITHKLINE BEECHAM PLC (GB) | 2000-01-05 | — | — | EP | disclosed |
| WO-1999062891-A1 | POTASSIUM CHANNEL INHIBITORS | ICAGEN, INC. (US) | 1999-12-09 | — | — | WO | disclosed |
| WO-1999062904-A1 | SULFONIC ACID OR SULFONYLAMINO N-(HETEROARALKYL)-AZAHETEROCYCLYLAMIDE COMPOUNDS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-12-09 | — | — | WO | disclosed |
| US-5998399-A | Guanidine derivatives useful in therapy as inhibitors of nitric oxide synthetase | ASTRA AKTIEBOLAG (SE) | 1999-12-07 | — | — | US | disclosed |
| EP-0495091-B1 | AICA RIBOSIDE ANALOGS | METABASIS THERAPEUTICS INC (US) | 1999-11-24 | — | — | EP | disclosed |
| WO-1999058499-A1 | PHENYLSULFONAMIDE-PHENYLETHYLAMINES USEFUL AS DOPAMINE RECEPTORS | PHARMACIA & UPJOHN COMPANY (US) | 1999-11-18 | — | — | WO | disclosed |
| US-5985872-A | THERAPEUTIC TREATMENT OF HERPES VIRAL INFECTION | G.D. SEARLE & CO. (US) | 1999-11-16 | — | — | US | disclosed |
| EP-0944386-A1 | SULFONIC ACID OR SULFONYLAMINO N-(HETEROARALKYL)-AZAHETEROCYCLYLAMIDE COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1999-09-29 | — | — | EP | disclosed |
| EP-0934276-A1 | ANTHRANILIC ACID DERIVATIVES AS MULTI DRUG RESISTANCE MODULATORS | XENOVA LIMITED (GB) | 1999-08-11 | — | — | EP | disclosed |
| EP-0738144-A4 | PHENYLMETHYL HEXANAMIDES, AND THE USE THEREOF | SMITHKLINE BEECHAM CORP (US) | 1999-06-30 | — | — | EP | disclosed |
| WO-1999031068-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS | SMITHKLINE BEECHAM PLC (GB) | 1999-06-24 | — | — | WO | disclosed |
| US-5914319-A | Antithrombotic agents | ELI LILLY AND COMPANY (US) | 1999-06-22 | — | — | US | disclosed |
| WO-1999025709-A1 | ISOQUINOLINE DERIVATIVES AND THEIR THERAPEUTICAL USE | SMITHKLINE BEECHAM P.L.C. (GB) | 1999-05-27 | — | — | WO | disclosed |
| EP-0915847-A1 | SUBSTITUTED SULFONAMIDES AS SELECTIVE BETA3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY | Merck & Co., Inc. (US) | 1999-05-19 | — | — | EP | disclosed |
| EP-0690851-B1 | GUANIDINE DERIVATIVES USEFUL IN THERAPY | ASTRA AB (SE) | 1999-05-19 | — | — | EP | disclosed |
| WO-1999021836-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS | SMITHKLINE BEECHAM PLC (GB) | 1999-05-06 | — | — | WO | disclosed |
| EP-0906283-A1 | SUBSTITUTED BENZAMIDE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS | SMITHKLINE BEECHAM PLC (GB) | 1999-04-07 | — | — | EP | disclosed |
| WO-1999014197-A1 | SUBSTITUTED ISOQUINOLINES AS ANTICONVULSIVANTS | SMITHKLINE BEECHAM PLC (GB) | 1999-03-25 | — | — | WO | disclosed |
| US-5885985-A | Guanidine derivatives useful in therapy | ASTRA AKTIEBOLAG (SE) | 1999-03-23 | — | — | US | disclosed |
| EP-0882066-A1 | PEPTIDE DERIVATIVES | ZENECA LIMITED (GB) | 1998-12-09 | — | — | EP | disclosed |
| WO-1998051393-A1 | SEPARATION OF A TWO PHASE MIXTURE BY FREEZING | RADLEYS COMBI-CHEM LIMITED (GB) | 1998-11-19 | — | — | WO | disclosed |
| WO-1998050358-A1 | INDOLE DERIVATIVES HAVING COMBINED 5HT1A, 5HT1B AND 5HT1D RECEPTOR ANTAGONIST ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 1998-11-12 | — | — | WO | disclosed |
| WO-1998041508-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS | SMITHKLINE BEECHAM PLC (GB) | 1998-09-24 | — | — | WO | disclosed |
| US-5807885-A | Amidine derivatives with nitric oxide synthetase activities | ASTRA AKTIEBOLAG (SE) | 1998-09-15 | — | — | US | disclosed |
| EP-0674622-B1 | TETRAHYDROCARBAZOLE DERIVATIVES AS 5-HT1-LIKE AGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1998-08-26 | — | — | EP | disclosed |
| JP-H10204046-A | ANTIMICROBIAL AND ANTIFOULING AGENT AND BROMOACETAMIDE DERIVATIVE | SAGAMI CHEM RES CENTER | 1998-08-04 | — | — | JP | disclosed |
| US-5777100-A | INCREASING LEVELS OF ADENOSINE, CARDIOVASCULAR, ISCHEMIA | GENSIA INC. (US) | 1998-07-07 | — | — | US | disclosed |
| WO-1998025611-A1 | SULFONIC ACID OR SULFONYLAMINO N-(HETEROARALKYL)-AZAHETEROCYCLYLAMIDE COMPOUNDS | RHÔNE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-06-18 | — | — | WO | disclosed |
| WO-1998017648-A1 | ANTHRANILIC ACID DERIVATIVES AS MULTI DRUG RESISTANCE MODULATORS | XENOVA LIMITED (GB) | 1998-04-30 | — | — | WO | disclosed |
| US-5726159-A | PEPTIDE THROMBIN INHIBITORS | ELI LILLY AND COMPANY (US) | 1998-03-10 | — | — | US | disclosed |
| WO-1998004526-A1 | SUBSTITUTED SULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY | MERCK & CO., INC. (US) | 1998-02-05 | — | — | WO | disclosed |
| US-5710130-A | HETEROCYCLIC SYNTHETIC PEPTIDES | ELI LILLY AND COMPANY (US) | 1998-01-20 | — | — | US | disclosed |
| US-5707966-A | Antithrombotic agents | ELI LILLY AND COMPANY (US) | 1998-01-13 | — | — | US | disclosed |
| US-5705515-A | HAVING REDUCED SIDE EFFECTS | MERCK & CO., INC. (US) | 1998-01-06 | — | — | US | disclosed |
| US-5705487-A | PEPTIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1998-01-06 | — | — | US | disclosed |
| WO-1997048683-A1 | SUBSTITUTED BENZAMIDE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS | SMITHKLINE BEECHAM PLC (GB) | 1997-12-24 | — | — | WO | disclosed |
| US-5679699-A | ANTIISCHEMIC AGENTS, HEART RATE LOWERING AGENTS | KALI-CHEMIE PHARMA GMBH (DE) | 1997-10-21 | — | — | US | disclosed |
| US-5674909-A | FOR TREATMENT OF CARDIOVASCULAR DISORDERS | ZAMBON GROUP (IT) | 1997-10-07 | — | — | US | disclosed |
| EP-0798292-A1 | ANILINE DERIVATIVES HAVING NITROGEN MONOXIDE SYNTHASE INHIBITORY ACTIVITY | Chugai Seiyaku Kabushiki Kaisha (JP) | 1997-10-01 | — | — | EP | disclosed |
| WO-1997031023-A1 | PEPTIDE DERIVATIVES | ZENECA LIMITED (GB) | 1997-08-28 | — | — | WO | disclosed |
| EP-0781126-A2 | DERIVATIVES OF 2-AMINO-1,2,3,4-TETRAHYDRO-NAPHTHALENE ACTIVE ON THE CARDIOVASCULAR SYSTEM | ZAMBON GROUP S.p.A. (IT) | 1997-07-02 | — | — | EP | disclosed |
| EP-0611003-B1 | Substituted phenyl sulfonamides as selective B3 agonists for the treatment of diabetes and obesity | MERCK & CO INC (US) | 1997-06-18 | — | — | EP | disclosed |
| US-5612331-A | Tetrahydrocarbazole derivatives as 5-HT1-like agonists | SMITHKLINE BEECHAM PLC (GB) | 1997-03-18 | — | — | US | disclosed |
| EP-0738144-A1 | PHENYLMETHYL HEXANAMIDES, AND THE USE THEREOF | SMITHKLINE BEECHAM CORPORATION (US) | 1996-10-23 | — | — | EP | disclosed |
| EP-0737680-A1 | (Phenylalkylaminoalkyloxyl)-hetero-aryl compounds, processes and intermediates for their preparation and medicaments containing these compounds | Kali-Chemie Pharma GmbH (DE) | 1996-10-16 | — | — | EP | disclosed |
| US-5547967-A | HYPOTENSIVE AGENT, ANTIISCHEMIC AGENT | KALI-CHEMIE PHARMA GMBH (DE) | 1996-08-20 | — | — | US | disclosed |
| US-5534440-A | ISOTHIOCYANATE, IONIZABLE GROUP | BIOMEDICAL RESEARCH CENTRE LIMITED (CA) | 1996-07-09 | — | — | US | disclosed |
| EP-0713483-A1 | AMIDINE DERIVATIVES WITH NITRIC OXIDE SYNTHETASE ACTIVITIES | Astra Aktiebolag (SE) | 1996-05-29 | — | — | EP | disclosed |
| WO-1996008228-A2 | DERIVATIVES OF 2-AMINO-1,2,3,4-TETRAHYDRO-NAPHTHALENE ACTIVE ON THE CARDIOVASCULAR SYSTEM | ZAMBON GROUP S.P.A. (IT) | 1996-03-21 | — | — | WO | disclosed |
| EP-0690851-A1 | GUANIDINE DERIVATIVES USEFUL IN THERAPY | Astra Aktiebolag (SE) | 1996-01-10 | — | — | EP | disclosed |
| EP-0573482-B1 | COMPOUNDS AND METHODS FOR SEQUENCING AMINO ACIDS | B R CENTRE LIMITED (CA) | 1995-12-27 | — | — | EP | disclosed |
| EP-0674622-A1 | TETRAHYDROCARBAZOLE DERIVATIVES AS 5-HT1-LIKE AGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1995-10-04 | — | — | EP | disclosed |
| EP-0672658-A1 | Antithrombotic agents | ELI LILLY AND COMPANY (US) | 1995-09-20 | — | — | EP | disclosed |
| US-5451677-A | Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity | MERCK & CO., INC. (US) | 1995-09-19 | — | — | US | disclosed |
| WO-1995023609-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 1995-09-08 | — | — | WO | disclosed |
| WO-1995017888-A1 | PHENYLMETHYL HEXANAMIDES, AND THE USE THEREOF | SMITHKLINE BEECHAM CORPORATION (US) | 1995-07-06 | — | — | WO | disclosed |
| WO-1995005363-A1 | AMIDINE DERIVATIVES WITH NITRIC OXIDE SYNTHETASE ACTIVITIES | ASTRA AKTIEBOLAG (SE) | 1995-02-23 | — | — | WO | disclosed |
| WO-1994021621-A1 | GUANIDINE DERIVATIVES USEFUL IN THERAPY | ASTRA AKTIEBOLAG (SE) | 1994-09-29 | — | — | WO | disclosed |
| WO-1994018161-A1 | SUBSTITUTED PHENYL SULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY | MERCK & CO., INC. (US) | 1994-08-18 | — | — | WO | disclosed |
| EP-0611003-A1 | Substituted phenyl sulfonamides as selective B3 agonists for the treatment of diabetes and obesity | MERCK & CO. INC. (US) | 1994-08-17 | — | — | EP | disclosed |
| WO-1994014773-A1 | TETRAHYDROCARBAZOLE DERIVATIVES AS 5-HT1-LIKE AGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1994-07-07 | — | — | WO | disclosed |
| EP-0369344-B1 | N-arylation of isatins | ABBOTT LAB (US) | 1994-04-06 | — | — | EP | disclosed |
| EP-0573482-A1 | COMPOUNDS AND METHODS FOR SEQUENCING AMINO ACIDS. | B R CENTRE LIMITED (CA) | 1993-12-15 | — | — | EP | disclosed |
| US-5240859-A | Coupling terminal amino acid with thioisocyanate, cleaving and identification; spectometrometric analysis | B.R. CENTRE LIMITED (CA) | 1993-08-31 | — | — | US | disclosed |
| EP-0542867-A4 | METHODS OF PREVENTING OR DECREASING TISSUE DAMAGE BY NOVEL ANTIOXIDANTS AND FREE RADICAL SCAVENGERS | — | 1993-07-28 | — | — | EP | disclosed |
| EP-0542867-A1 | METHODS OF PREVENTING OR DECREASING TISSUE DAMAGE BY NOVEL ANTIOXIDANTS AND FREE RADICAL SCAVENGERS | GENSIA, INC. (US) | 1993-05-26 | — | — | EP | disclosed |
| EP-0495091-A4 | AICA RIBOSIDE ANALOGS | — | 1993-01-07 | — | — | EP | disclosed |
| US-5151518-A | N-arylation of isatins | ABBOTT LABORATORIES (US) | 1992-09-29 | — | — | US | disclosed |
| WO-1992014702-A1 | COMPOUNDS AND METHODS FOR SEQUENCING AMINO ACIDS | B.R. CENTRE LIMITED (CA) | 1992-09-03 | — | — | WO | disclosed |
| EP-0495091-A1 | AICA RIBOSIDE ANALOGS | GENSIA, INC. (US) | 1992-07-22 | — | — | EP | disclosed |
| WO-1992002214-A1 | AICA RIBOSIDE ANALOGS | GENSIA PHARMACEUTICALS, INC. (US) | 1992-02-20 | — | — | WO | disclosed |
| WO-1992002213-A1 | METHODS OF PREVENTING OR DECREASING TISSUE DAMAGE BY NOVEL ANTIOXIDANTS AND FREE RADICAL SCAVENGERS | GENSIA PHARMACEUTICALS, INC. (US) | 1992-02-20 | — | — | WO | disclosed |
| US-5030639-A | N-substituted-5,6-dimethoxy-1,2-benzisoxazole-3-propanamine and related compounds as analgesic and hypotensive agents | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1991-07-09 | — | — | US | disclosed |
| US-5008264-A | N-substituted-5,6-dimethoxy-1,2-benzisoxazole-3-propanamine and related compounds as analgesic and hypotensive agents | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1991-04-16 | — | — | US | disclosed |
| EP-0322692-B1 | HETEROCYCLICALLY SUBSTITUTED ALKYL SULFONE AMIDES, METHOD FOR THEIR PREPARATION, AND PHARMACEUTICAL PREPARATIONS | Roche Diagnostics GmbH (DE) | 1991-03-06 | — | — | EP | disclosed |
| US-4980365-A | N-substituted-5,6-dimethoxy-1,2-benzisoxazole-3-propanamine and related compounds as analgesic and hypotensive agents | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1990-12-25 | — | — | US | disclosed |
| US-4931462-A | Heterocyclic substituted alkylsulphonamides pharmaceutical compositions containing them, and arterial disease treatment therewith | BOEHRINGER MANNHEIM GMBH (DE) | 1990-06-05 | — | — | US | disclosed |
| EP-0369344-A1 | N-arylation of isatins | ABBOTT LABORATORIES (US) | 1990-05-23 | — | — | EP | disclosed |
| US-4855314-A | VASOCONTRICTORS, TREATMENT OF MIGRAINES, 3-(AMINO-ETHYL)-5-(PHENYL(ALKYL)-CARBONYL OR SULFONYL-AMINOALKYL SUBSTITUTED | GLAXO GROUP LIMITED (GB) | 1989-08-08 | — | — | US | disclosed |
| EP-0322692-A1 | Heterocyclically substituted alkyl sulfone amides, method for their preparation, and pharmaceutical preparations | Roche Diagnostics GmbH (DE) | 1989-07-05 | — | — | EP | disclosed |
| EP-0299349-A2 | N-substituted-5,6-dimethoxy-1,2-benzisoxazole-3-propanamine and related compounds, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1989-01-18 | — | — | EP | disclosed |
| EP-0240096-A1 | Indole derivatives having a selective vasoconstrictor activity | GLAXO GROUP LIMITED (GB) | 1987-10-07 | — | — | EP | disclosed |
| EP-0240096-A1 | Indole derivatives having a selective vasoconstrictor activity | GLAXO GROUP LIMITED (GB) | 1987-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030022895-A1 | 2-Amino-benzoxazinones for the treatment of viral infections | IFNAR1, IL4I1, HAX1 | KCNH2 955/4885HRH3 335/4885CA2 1655/4885 |
| US-20040019084-A1 | New derivatives of lipoic acid, their preparation, their use as medicaments and the pharmaceutical compositions containing them | NOS1, NOS2, LPO | KCNH2 4746/4885HRH3 4234/4885CA2 477/4885 |
| US-20220106312-A1 | ACETAMIDO-PHENYLTETRAZOLE DERIVATIVES AND METHODS OF USING THE SAME | ABCB1, CYP3A5, CYP3A7 | KCNH2 2416/4885HRH3 4351/4885CA2 1818/4885 |
| US-20200308568-A1 | ALCOHOL STABLE ENZYMES | ADH1C, ADH5, ADH1A | KCNH2 4107/4885HRH3 3981/4885CA2 2653/4885 |
| US-20050004190-A1 | Alpha-form or beta-form crystal of acetanilide derivative | IAPP, AMY1A, AMY2A | KCNH2 2621/4885HRH3 3063/4885CA2 72/4885 |
| US-20050032793-A1 | 2-amino-benzoxazinones for the treatment of viral infections | IFNAR1, IL4I1, ACE2 | KCNH2 1120/4885HRH3 147/4885CA2 1836/4885 |
| US-20150272978-A1 | METHODS, COMPOSITIONS, AND FORMULATIONS FOR PREVENTING OR REDUCING ADVERSE EFFECTS IN A PATIENT | TNNC1, ASAH2, PGF | KCNH2 1180/4885HRH3 4169/4885CA2 324/4885 |
| US-20040014766-A1 | Amide substituted xanthine derivatives | GYS2, GLS2, PYGL | KCNH2 4459/4885HRH3 2103/4885CA2 1606/4885 |
| US-20050119258-A1 | A1 adenosine receptor antagonists | ADORA1, ADORA2A, ADORA3 | KCNH2 914/4885HRH3 441/4885CA2 2842/4885 |
| US-20040192708-A1 | Sulfonamide substituted xanthine derivatives | GYS2, SLC5A1, SLC5A2 | KCNH2 4085/4885HRH3 2649/4885CA2 1317/4885 |
| US-20150158901-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | CCNO, PTGDR, CCNE1 | KCNH2 2769/4885HRH3 1632/4885CA2 2606/4885 |
| US-20180016300-A1 | COMPOUNDS, LINKER-DRUGS AND LIGAND-DRUG CONJUGATES | SLC43A1, HCAR3, SLC7A1 | KCNH2 1047/4885HRH3 36/4885CA2 1440/4885 |
| US-20030018045-A1 | Heterocyclic beta-3 adrenergic receptor agonists | ADRB2, ADRB1, ADRB3 | KCNH2 564/4885HRH3 429/4885CA2 2958/4885 |
| US-20110282031-A1 | A1 ADENOSINE RECEPTOR DIAGNOSTIC PROBES | ADORA1, ADORA3, ADORA2A | KCNH2 1187/4885HRH3 172/4885CA2 2890/4885 |
| US-20070161629-A1 | A1 Adenosine Receptor Antagonists | ADORA1, ADORA2A, ADORA3 | KCNH2 914/4885HRH3 441/4885CA2 2842/4885 |
| US-10023530-B2 | Diamine, polyamic acid, and polyimide | H1-2, H1-4, H1-0 | KCNH2 3803/4885HRH3 28/4885CA2 2174/4885 |
| US-20250073341-A1 | BIFUNCTIONAL HETEROCYCLIC COMPOUND HAVING BTK DEGRADATION FUNCTION VIA UBIQUITIN PROTEASOME PATHWAY, AND USE THEREOF | BTK, XIAP, SYK | KCNH2 4295/4885HRH3 2021/4885CA2 4492/4885 |
| US-20200207742-A1 | DIPROVOCIMS: A NEW AND POTENT CLASS OF TLR AGONISTS | TLR1, TLR4, TLR2 | KCNH2 3448/4885HRH3 516/4885CA2 4216/4885 |
| US-20030105107-A1 | Novel lipoic acid heterocyclic or benzene derivatives, preparation and use thereof as medicines | LTC4S, LPO, COASY | KCNH2 3893/4885HRH3 2960/4885CA2 633/4885 |
| US-20190248956-A1 | POLY(L-LYSINE ISOLPHTHALAMIDE) (PLP) POLYMERS WITH HYDROPHOBIC PENDANT CHAINS | PLP2, LNPEP, PLPBP | KCNH2 655/4885HRH3 605/4885CA2 3695/4885 |
| US-20090093529-A1 | REMEDY FOR OVERACTIVE BLADDER COMPRISING ACETIC ACID ANILIDE DERIVATIVE AS THE ACTIVE INGREDIENT | MYLK, ALKBH2, MYH2 | KCNH2 899/4885HRH3 1635/4885CA2 46/4885 |
| US-20090149456-A1 | 2-Pyrimidinyl Pyrazolopyridine ErbB Kinase Inhibitors | ERBB2, ERBB3, ERBB4 | KCNH2 2635/4885HRH3 2577/4885CA2 3038/4885 |
| US-20050227991-A1 | New heterocyclic or benzenic derivatives of lipoic acid, their preparation and their use as medicaments | LPO, LTC4S, BBOX1 | KCNH2 3944/4885HRH3 2151/4885CA2 488/4885 |
| US-20120101115-A1 | Compounds For Inducing Cellular Apoptosis | BAD, BAX, CASP3 | KCNH2 4382/4885HRH3 3578/4885CA2 4156/4885 |
| US-20120252747-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | CCNO, PTGDR, CCNE1 | KCNH2 2769/4885HRH3 1632/4885CA2 2606/4885 |
| US-20050154011-A1 | Tetrahydroisoquinolnyl sulfamic acids | PTPRS, PTPRJ, PTPRM | KCNH2 4587/4885HRH3 4023/4885CA2 2129/4885 |
| US-11292878-B2 | Poly(L-lysine isolphthalamide) (PLP) polymers with hydrophobic pendant chains | PLP2, LNPEP, PLPBP | KCNH2 655/4885HRH3 605/4885CA2 3695/4885 |
| US-20060293273-A1 | Methods, Compositions, and Formulations for Preventing or Reducing Adverse Effects in a Patient | TNNC1, ASAH2, PGF | KCNH2 1180/4885HRH3 4169/4885CA2 324/4885 |
| US-10683327-B2 | Compounds, linker-drugs and ligand-drug conjugates | SLC43A1, HCAR3, SLC7A1 | KCNH2 1047/4885HRH3 36/4885CA2 1440/4885 |
| US-20080175891-A1 | METHODS, COMPOSITIONS, AND FORMULATIONS FOR PREVENTING OR REDUCING ADVERSE EFFECTS IN A PATIENT | NNT, PGF, GART | KCNH2 726/4885HRH3 2928/4885CA2 336/4885 |
| US-20020040023-A1 | Substituted arylsulfides, arylsulfoxides and arylsulfones as beta-3 adrenergic receptor agonists | ADRB1, ADRB3, GPR119 | KCNH2 1295/4885HRH3 1010/4885CA2 4077/4885 |
| US-20050197329-A1 | Derivatives of N-(iminomethyl)amines, their preparation, their use as medicaments and the pharmaceutical compositions containing them | NOS1, NOS2, NOS3 | KCNH2 3486/4885HRH3 370/4885CA2 3229/4885 |
| US-20030036551-A1 | Novel compounds | SCN1B, CNR1, SCN1A | KCNH2 11/4885HRH3 322/4885CA2 678/4885 |
| US-10233212-B2 | Compounds, linker-drugs and ligand-drug conjugates | SLC43A1, HCAR3, SLC7A1 | KCNH2 1047/4885HRH3 36/4885CA2 1440/4885 |
| US-20040209912-A1 | Substituted isoquinoline derivatives and their use as anticonvulsants | INA, GRIN2C, GRIN2A | KCNH2 183/4885HRH3 541/4885CA2 1450/4885 |
| US-20150094439-A1 | STABLE POLYMERIZABLE UV-ABSORBING COLORANT FOR INTRAOCULAR LENS | UACA, CRYAA, ALDH1A2 | KCNH2 1328/4885HRH3 31/4885CA2 326/4885 |
| US-20170283427-A1 | COMPOUNDS FOR THE INHIBITION OF CYCLOPHILINS AND USES THEREOF | PPIG, PPIH, FKBP2 | KCNH2 4476/4885HRH3 3541/4885CA2 3003/4885 |
| US-10287251-B2 | Pyrazole derivative or pharmaceutically acceptable salt thereof | TRPM8, HCN3, HCN4 | KCNH2 85/4885HRH3 107/4885CA2 475/4885 |
| US-20090111850-A1 | Amino-Substituted Ethylamino Beta2 Adrenergic Receptor Agonists | ADRB2, ADRB1, ADRA2A | KCNH2 619/4885HRH3 258/4885CA2 2542/4885 |
| US-20010016657-A1 | Substituted isoquinoline derivatives and their use as anticonvulsants | INA, GRIN2C, GRIN2A | KCNH2 183/4885HRH3 541/4885CA2 1450/4885 |
| US-20070282105-A1 | A1 ADENOSINE RECEPTOR ANTAGONISTS | ADORA1, ADORA3, ADORA2A | KCNH2 1241/4885HRH3 461/4885CA2 3623/4885 |
| US-20050027009-A1 | New derivatives of N-(iminomethyl)amines, their preparation, their use as medicaments and the pharmaceutical compositions containing them | NOS1, NOS2, NOS3 | KCNH2 3671/4885HRH3 274/4885CA2 3468/4885 |
| US-20110230530-A1 | REMEDY FOR OVERACTIVE BLADDER COMPRISING ACETIC ACID ANILIDE DERIVATIVE AS THE ACTIVE INGREDIENT | MYLK, ALKBH2, MYH2 | KCNH2 899/4885HRH3 1635/4885CA2 46/4885 |
| US-20250074904-A1 | NSD2-TARGETED CHECMICAL DEGRADERTS AND COMPOSITIONS AND METHODS OF USE THEREOF | NCOR2, NSD2, NCOR1 | KCNH2 4860/4885HRH3 3277/4885CA2 4561/4885 |
| US-20160264520-A1 | NOVEL DIAMINE, POLYAMIC ACID, AND POLYIMIDE | H1-4, H1-2, H1-5 | KCNH2 3737/4885HRH3 28/4885CA2 2161/4885 |
| US-20020123495-A1 | Heteroarylacryloylaminoalkyl-substituted benzenesulfonamide derivatives, their preparation, their use and pharmaceutical preparations comprising them | KCNJ11, HCN3, CACNA1E | KCNH2 15/4885HRH3 286/4885CA2 1194/4885 |
| US-20250082762-A1 | NOVEL BIFUNCTIONAL HETEROCYCLIC COMPOUND HAVING BTK DEGRADATION FUNCTION VIA UBIQUITIN PROTEASOME PATHWAY, AND USE THEREOF | BTK, XIAP, UBE3C | KCNH2 4427/4885HRH3 2216/4885CA2 4493/4885 |
| US-20050256167-A1 | Preparation and use of imidazole derivatives for treatment of obesity | GPR119, GIPR, PGC | KCNH2 1433/4885HRH3 804/4885CA2 2743/4885 |
| US-20080293705-A1 | A1 ADENOSINE RECEPTOR ANTAGONISTS | ADORA1, ADORA2A, ADORA3 | KCNH2 914/4885HRH3 441/4885CA2 2842/4885 |
| US-20210155594-A1 | HETEROCYCLIC DERIVATIVES AND USE THEREOF | STAT3, JAK2, IRF3 | KCNH2 4839/4885HRH3 4110/4885CA2 4451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.